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A B S T R A C T
Background
Assisted reproduction techniques (ART) such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) can help
subfertile couples to create a family. It is necessary to induce multiple follicles; this is achieved by follicle stimulating hormone (FSH)
injections. Current treatment regimens prescribe daily injections of FSH (urinary FSH with or without luteinizing hormone (LH)
injections or recombinant FSH (rFSH)).
Recombinant DNA technologies have produced a new recombinant molecule which is a long-acting FSH, named corifollitropin alfa
(Elonva) or FSH-CTP. A single dose of long-acting FSH is able to keep the circulating FSH level above the threshold necessary to
support multi-follicular growth for an entire week. The optimal dose of long-acting FSH is still being determined. A single injection of
long-acting FSH can replace seven daily FSH injections during the first week of controlled ovarian stimulation (COS) and can make
assisted reproduction more patient friendly.
Objectives
To compare the effectiveness of long-acting FSH versus daily FSH in terms of pregnancy and safety outcomes in women undergoing
IVF or ICSI treatment cycles.
Search methods
We searched the following electronic databases, trial registers and websites: the Cochrane Central Register of Controlled Trials (CEN-
TRAL), the Menstrual Disorders and Subfertility Group (MDSG) Specialised Register, MEDLINE, EMBASE, PsycINFO, CINAHL,
electronic trial registers for ongoing and registered trials, citation indexes, conference abstracts in the ISI Web of Knowledge, LILACS,
Clinical Study Results (for clinical trial results of marketed pharmaceuticals), PubMed and OpenSIGLE (10 October 2011). We also
carried out handsearches.
Selection criteria
All randomised controlled trials (RCTs) comparing long-acting FSH versus daily FSH in women who were part of a couple with
subfertility and undertaking IVF or ICSI treatment cycles with a GnRH antagonist or agonist protocol were included.
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Data collection and analysis
Data extraction and assessment of risk of bias was independently done by two review authors. Original trial authors were contacted
in the case of missing data. We calculated Peto odds ratios for each outcome; our primary outcomes were live birth rate and ovarian
hyperstimulation syndrome (OHSS) rate.
Main results
We included four RCTs with a total of 2335 participants. A comparison of long-acting FSH versus daily FSH did not show evidence
of difference in effect on overall live birth rate (Peto OR 0.92; 95% CI 0.76 to 1.10, 4 RCTs, 2335 women) or OHSS (Peto OR 1.12;
95% CI 0.79 to 1.60, 4 RCTs, 2335 women). We compared subgroups by dose of long-acting FSH. There was evidence of reduced
live birth rate in women who received lower doses (60 to 120 µg) of long-acting FSH compared to daily FSH (Peto OR 0.60; 95% CI
0.40 to 0.91, 3 RCTs, 645 women). There was no evidence of effect on live births in the medium dose subgroup (Peto OR 1.03; 95%
CI 0.84 to 1.27) and no evidence of effect on clinical pregnancy rate, ongoing pregnancy rate, multiple pregnancy rate, miscarriage
rate or ectopic pregnancy rate.
Authors’ conclusions
The use of a medium dose of long-acting FSH is a safe treatment option and equally effective compared to daily FSH. Further research
is needed to determine if long-acting FSH is safe and effective for use in hyper- or poor responders and in women with all causes of
subfertility.
P L A I N L A N G U A G E S U M M A R Y
Long-acting FSH versus daily FSH for women undergoing assisted reproduction
For definitions of terminology see the Glossary
Assisted reproduction techniques such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) can help subfertile
couples to create a family. In a normal cycle only one egg will mature and is suitable for fertilisation. When IVF or ICSI are performed,
the fertilisation of the egg takes place outside the woman’s body. Multiple eggs are needed for IVF and ICSI to increase the number
of suitable fertilised eggs for transfer to the woman. After the eggs are fertilised, they become embryos. One, two and sometimes three
embryos are transferred; the other embryos can be cryopreserved and transferred in a later treatment cycle.
The development of multiple eggs is achieved by controlled ovarian stimulation (COS) with follicle stimulation hormone (FSH).
Current treatment regimens prescribe daily injections of FSH during the first seven days of COS. A new treatment is available and one
single injection of long-acting FSH, called corifollitropin alfa, can replace the first seven injections of FSH. The optimal dose of long-
acting FSH is still being determined.
The aim of this review was to compare the effectiveness of long-acting FSH versus daily FSH in terms of pregnancy and safety outcomes
in women undergoing IVF or ICSI treatment cycles. We included four trials involving a total of 2335 women. The results suggested
that a medium dose of long-acting FSH provides similar numbers of live births as daily FSH. The serious adverse event ovarian
hyperstimulation syndrome (OHSS) occurred equally with both treatments.
It can be concluded that medium dose long-acting FSH is a safe treatment option and is equally effective compared to daily FSH
injections.
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B A C K G R O U N D
For definitions of terminology see the Glossary (Appendix 1)
Description of the condition
Infertility affects 10% to 15% of couples trying to conceive (Evers
2002;Gnoth 2005). Assisted reproduction techniques (ART) such
as in vitro fertilisation (IVF) and intracytoplasmic sperm injec-
tion (ICSI) can help these couples to create a family. In ART it
is necessary to induce multiple follicles. This is achieved by con-
trolled ovarian stimulation (COS) with follicle stimulating hor-
mone (FSH) injections.
Current treatment regimens prescribe daily injections of FSH (uri-
nary FSHwith or without luteinizing hormone (LH) injections or
recombinant FSH (rFSH)). The FSH injections are usually started
from cycle day two. Prevention of a premature ovulation due to a
LH surge can be accomplished with gonadotropin-releasing hor-
mone (GnRH) agonists or GnRH antagonists. Some clinicians
consider antagonists to be the first choice in COS due to their im-
mediate action, lack of side effects (for example lower incidence of
ovarian hyperstimulation syndrome (OHSS)), the need for fewer
injections and the same live birth rate as with agonists (Al-Inany
2011; Tarlatzis 2007). Other clinicians consider agonists as the
first choice in COS due to a higher pregnancy rate (Maheshwari
2011). Antagonist injections start on day five or six (see Figure
1) whereas agonist injections start two to four weeks prior to the
stimulation (see Figure 2).
Figure 1. Schematic representation of therapeutic interventions during ovarian stimulation with rFSH in a
GnRH antagonist protocol (Source:De Greef 2010)
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Figure 2. Schematic representation of therapeutic interventions during ovarian stimulation with rFSH in a
GnRH agonist protocol (Source:De Greef 2010)
FSH andGnRH agonist or antagonist injections are continued up
to and including the day the leading follicle reaches 18 to 20 mm
(Heineman 2007). On this day, 34 to 36 hours prior to the ovum
pick-up, human chorionic gonadotropin (hCG) is administered
by injection leading to the final maturation necessary to produce
the ovulation (see Figure 1; Figure 2). Two days (34 to 36 hours)
later several oocytes are ready for ovum pick-up. After the pick-up,
the oocytes are fertilised by IVF or ICSI. Two to five days after the
fertilisation one, two or sometimes three embryos are transferred
(Kovacs 2011).
Description of the intervention
Daily injections of rFSH are required to maintain steady state
levels of FSH in the blood that are above the threshold for follicular
development and ongoing maturation, due to its relatively short
half-life and rapid metabolic clearance. The daily subcutaneous
administration and side effects of the rFSH preparations can cause
discomfort and be a physical burden to the patient. Many couples
withdrawprematurely from IVFor ICSI due to emotional distress,
which limits their chances of pregnancy. A German study showed
withdrawal of 40% of non-pregnant couples after just one cycle
of IVF due to emotional distress (Schroder 2004). For this reason,
a patient friendly therapy regimen should be developed.
Recombinant DNA technologies have produced a new recombi-
nant molecule which consists of the α-subunit of human FSH
and a hybrid subunit consisting of the carboxyl-terminal peptide
of the β-subunit of human chorionic gonadotrophin (hCG) cou-
pled with the FSHβ-subunit. This molecule is a long-acting FSH,
named corifollitropin alfa (Elonva) or FSH-CTP (Fauser 2009;
Koper 2008). A single injection of long-acting FSH on the first
day of the stimulation can replace the first seven daily injections of
rFSH andmake assisted reproduction more acceptable to patients.
The administration of long-acting FSH involves one subcutaneous
injection on the first day of COS. The dose of long-acting FSH
should be as low as possible to avoid ovarian hyperstimulation syn-
drome (OHSS) but high enough to support COS over the seven
days. De Greef 2010 investigated 100 µg for women weighing <
60 kg and 150 µg for women weighing > 60 kg and the doses
were proven to be adequate. The optimal dose of long-acting FSH
is still under investigation. From day seven, the same treatment
protocol as rFSH is used (see Figure 3; Figure 4).
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Figure 3. Schematic representation of therapeutic interventions during ovarian stimulation with long-
acting FSH (Corifollitropin alfa) in a GnRH antagonist protocol (Source: De Greef 2010)
Figure 4. Schematic representation of therapeutic interventions during ovarian stimulation with long-
acting FSH (Corifollitropin alfa) in a GnRH agonist protocol (Source:De Greef 2010)
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How the intervention might work
Long-acting FSH has, compared with rFSH, an approximately
two-fold longer elimination half-life and an almost four-fold ex-
tended time to peak serum levels (Devroey 2009; Duijkers 2002).
Due to this pharmacokinetic profile, a single dose of long-acting
FSH is able to keep the circulating FSH level above the threshold
necessary to support multi-follicular growth for an entire week
(Devroey 2009; Koper 2008). As such, a single injection of long-
acting FSH can replace seven daily rFSH injections during the
first week of COS.
Why it is important to do this review
The development of this new treatment regimen may provide
similar or better success rates with fewer injections. It may help to
reduce the treatment burden and make the therapy more patient
friendly. On the other hand it could also be more costly. This
review considered the evidence from randomised controlled trials
for the use of long-acting FSH on pregnancy and safety outcomes.
O B J E C T I V E S
To compare the effectiveness of long-acting FSH versus daily FSH
in terms of pregnancy and safety outcomes in women undergoing
IVF or ICSI treatment cycles.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) were included in this review.
Only trials that were either clearly randomised or claimed to be
randomised and did not have evidence of inadequate sequence
generation, such as allocation by date of birth or hospital number,
were included.Weplanned to include cross-over trials in the review
but we did not find any cross-over trials comparing long-acting
FSH with daily FSH.
Types of participants
Women with subfertility and undertaking IVF or ICSI treatment
cycles with a GnRH antagonist or agonist protocol were included.
Types of interventions
Trials comparing long-acting FSH versus daily FSH were eligible
for inclusion. Any dose was included.
Types of outcome measures
Primary outcomes
Effectiveness
• Live birth rate per woman randomised, defined as the
delivery of one or more living babies after 20 completed weeks of
gestation. When there were multiple live births (e.g. twins or
triplets) these were counted as one live birth event
Adverse
• Ovarian hyperstimulation syndrome (OHSS) rate per
woman randomised
Secondary outcomes
Effectiveness
• Ongoing pregnancy rate per woman randomised, defined as
evidence of a gestational sac with fetal heart motion at 12 weeks,
confirmed by ultrasound
• Clinical pregnancy rate per woman randomised, defined as
the presence of a gestational sac with or without a fetal heart
beat, confirmed by ultrasound
Adverse
• Multiple pregnancy rate per woman randomised, counted
as one live birth event
• Miscarriage rate per woman randomised
• Any other adverse event per woman randomised (including
ectopic pregnancy, fetal abnormalities, drug side effects and
infection)
Process
• Patient satisfaction with the treatment
Search methods for identification of studies
All published and unpublished RCTs studying long-acting FSH
versus daily FSH were sought. We used the following search strat-
egy, without language restriction and in consultation with the
Cochrane Menstrual Disorders and Subfertility Group (MDSG)
Trials Search Co-ordinator.
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Electronic searches
The following electronic databases, trial registers andwebsiteswere
searched using Ovid software.
• Cochrane Central Register of Controlled Trials
(CENTRAL), see Appendix 2.
• The Menstrual Disorders and Subfertility Group (MDSG)
Specialised Register of controlled trials, see Appendix 3.
• MEDLINE, see Appendix 4.
• EMBASE, see Appendix 5.
• PsycINFO, see Appendix 6.
• CINAHL, see Appendix 7.
The MEDLINE search was combined with the Cochrane highly
sensitive search strategy for identifying randomised trials that ap-
pears in the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). The EMBASE search was combined with
trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN).
Other electronic sources of trials included the following.
• Trial registers for ongoing and registered trials: ’Current
Controlled Trials’ (http://www.controlled-trials.com/);
’ClinicalTrials.gov’, a service of the US National Institutes of
Health (http://clinicaltrials.gov/ct2/home).
• The World Health Organization International Trials
Registry Platform search portal (http://www.who.int/trialsearch/
Default.aspx).
• Citation indexes (http://scientific.thomson.com/products/
sci/).
• Conference abstracts in the ISI Web of Knowledge (http://
isiwebofknowledge.com/), see Appendix 8.
• LILACS database, as a source of trials from the Portuguese
and Spanish speaking world (htpp://regional.bvsalud.org/php/
index.php?lang=en) (choose ’LILACS’ in ’all sources’ drop-down
box).
• Clinical Study Results, for clinical trials of marketed
pharmaceuticals (http://www.clinicalstudyresults.org/).
• PubMed (http://www.ncbi.nlm.nih.gov/pubmed/), the
random control filter for PubMed was taken from the searching
chapter of the Cochrane Handbook for Systematic Reviews of
Interventions.
• OpenSIGLE database for grey literature from Europe (
http://opensigle.inist.fr/).
Searching other resources
The reference lists of articles retrieved by the search were hand-
searched and personal contact was made with experts in the field
and with the manufacturers of long-acting FSH in order to obtain
any additional, relevant data.
Data collection and analysis
Data collection and analysis was conducted in accordance with the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011).
Selection of studies
Two review authors independently scanned the titles and abstracts
of articles retrieved by the search and removed those that were
very clearly irrelevant. Full texts of all potentially eligible studies
were retrieved. Two review authors independently examined the
full text articles for compliance with the inclusion criteria and se-
lected studies eligible for inclusion in the review. We discussed any
disagreement or doubt as to whether a study was eligible for in-
clusion or not with a third review author and achieved consensus.
A list of the excluded studies and the reasons for exclusion are
provided in the ’Characteristics of excluded studies’ table.
Data extraction and management
Data were extracted from eligible studies using a data extraction
form designed and pilot-tested by the authors. Where studies had
multiple publications, the main trial report was used as the ref-
erence and additional details were supplemented from secondary
papers. The review authors corresponded with study investigators
in order to resolve any data queries, as required. Two review au-
thors independently extracted the data. Any disagreement between
these review authors was resolved by a third review author.
Assessment of risk of bias in included studies
The included studies were assessed for risk of bias using the
Cochrane risk of bias assessment tool, which recommends the ex-
plicit reporting of the following domains.
1. Random sequence generation (selection bias)
◦ Adequate: use of central computer randomisation,
independent central randomisation office, on-site computer
from which assignment could only be determined after entering
patient data, random number table or serially numbered and
sealed opaque envelopes
◦ Inadequate: use of non-opaque envelopes or
systematic methods (e.g. date of birth, medical record number,
day of the week presenting)
◦ Unclear: insufficient information about the process of
sequence generation
2. Allocation concealment (selection bias)
◦ Adequate: sequentially numbered and identical drug
containers were used
◦ Inadequate: use of open random allocation (e.g. date
of birth, medical record number, day of the week presenting)
◦ Unclear: insufficient information about the process of
allocation concealment
3. Blinding of participants, researchers and care providers
(performance bias)
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◦ Adequate: blinding of the participants, researchers and
the care providers, or incomplete or no blinding was used but
was not likely to influence outcomes
◦ Inadequate: no blinding or incomplete blinding was
used and likely to influence the outcomes
◦ Unclear: insufficient information about the process of
blinding the participants, researchers and care providers
4. Blinding of the outcome assessor (detection bias)
◦ Adequate: blinding of the researchers or incomplete
blinding had no effect on the outcome measurement
◦ Inadequate: no blinding of the researchers, or
incomplete blinding had influence on the outcomes
◦ Unclear: insufficient information about the process of
blinding the outcome assessor
5. Incomplete outcome data (attrition bias)
◦ Adequate: there were no missing data, or reasons for
missing data may not influence the outcomes
◦ Inadequate: reasons for missing data may influence the
outcomes
◦ Unclear: insufficient information about the
completeness of outcome data
6. Selective outcome reporting (reporting bias)
◦ Adequate: all pre-specified outcomes in the protocol
have been published, or no protocol available but it was clear all
pre-specified outcomes were reported
◦ Inadequate: not all pre-specified outcomes in the
protocol were reported
◦ Unclear: insufficient information about the process of
outcome reporting
7. Other potential sources of bias
◦ Adequate: the study was free of other biases
◦ Inadequate: other biases were present
◦ Unclear: insufficient information about the other
sources of bias
Two authors assessed these seven domains as ’low risk of bias’ (ad-
equate), ’high risk of bias’ (inadequate), or ’unclear risk of bias’
(unclear). The assessments made by the two authors were com-
pared and any disagreements were resolved by consensus or by
discussion with a third author. The conclusion is presented in the
’Risk of bias’ table and was incorporated into the interpretation of
review findings by means of sensitivity analyses.
Measures of treatment effect
We used the dichotomous data measures and expressed the results
in the control and intervention groups of each study as Peto odds
ratios (OR) with 95% confidence intervals (CI).
Unit of analysis issues
The primary analysis was per woman randomised. All included
studies reported data per woman. Multiple live births (for example
twins or triplets) were counted as one live birth event.
Dealing with missing data
In the case of missing data from the included studies, we contacted
the original investigators to request the relevant missing data. We
did not received the requested data so we made an imputation of
individual values for the primary outcomes only. Live births were
assumed not to have occurred in participants without a reported
outcome. For other outcomes, only the available data were anal-
ysed.
We analysed all data on an intention-to-treat (ITT) basis.
Assessment of heterogeneity
We considered whether the clinical and methodological charac-
teristics of the included studies were sufficiently similar for meta-
analysis to provide a meaningful summary. We used the I2 statistic
to assess the impact of the heterogeneity on the meta-analysis. We
interpret the result of the I2 statistic as follows:
• 0% to 40%, might not be important;
• 30% to 60%, may represent moderate heterogeneity;
• 50% to 90%, may represent substantial heterogeneity;
• 75% to 100%, considerable heterogeneity (Higgins 2011).
We did not find an I2 statistic measurement greater than 50%,
which means that there was no substantial heterogeneity (Higgins
2011). For this reason,we didnot carry out any sensitivity analyses.
Assessment of reporting biases
We have taken care to search for within trial selective reporting,
such as trials failing to report obvious outcomes or reporting them
in insufficient detail to allow inclusion. We sought published pro-
tocols to look for any pre-planned outcomes that may not have
been reported and compared the outcomes between the protocol
and the final published study.
We planned to undertake informal assessment if included studies
failed to report the primary outcome of live birth, but all studies
reported live birth.
In view of the difficulty of detecting and correcting for publication
bias and other reporting biases, we aimed tominimise the potential
impact by ensuring a comprehensive search for eligible studies.We
were alert for duplication of data. To investigate the potential for
publication bias, we planned to use a funnel plot if there were
10 or more studies in an analysis but due to the small number of
studies per subgroup this was not possible.
Data synthesis
We carried out the statistical analysis using Review Manager ver-
sion 5.1. We used a fixed-effect model to combine the data from
primary studies. We planned to perform a random-effects meta-
analysis in the case of substantial heterogeneity, but this was not
necessary.
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Subgroup analysis and investigation of heterogeneity
Data were analysed in the following subgroups.
Dose of long-acting FSH:
1. low dose (60 to 120 µg);
2. medium dose (150 to 180 µg);
3. high dose (240 µg).
We planned to do subgroup analyses on: women’s age; weight;
body mass index (BMI); day of starting GnRH antagonist; and
poor responders to ovarian stimulation. However, we were not
able to perform these subgroup analyses due to insufficient infor-
mation.
Sensitivity analysis
We planned to conduct sensitivity analyses for the primary out-
comes to determine whether the conclusions were robust regard-
ing the eligibility and analysis of studies. Because we did not find
substantial heterogeneity, we did not carry out the sensitivity anal-
yses.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
See:Characteristics of included studies, Characteristics of excluded
studies, Characteristics of ongoing studies
Results of the search
See: study flow diagram Figure 5
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Figure 5. Study flow diagram
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The search was done on 10 October 2011 (for our search strat-
egy see Methods). The search strings as stated in Appendix 2;
Appendix 3; Appendix 4; Appendix 5; Appendix 6; Appendix
7; Appendix 8 retrieved 107 articles. We also searched LILICS,
metaRegister of Controlled Trials-active registers, WHO Interna-
tional Trials Registry Platform, clinicaltrials.gov, clinicalstudyre-
sults.org, OpenSIGLE and PubMed (MeSH terms used) using the
keywords ’corifollitropin’, ’corifollitropin alfa’, ’corifollitropin alpha’,
’ORG 36286’, ’Elonva’, ’FSH-CTP’, ’long-acting FSH’, ’long acting
FSH’. This search retrieved 79 reports, another three reports were
found by using other methods such as handsearching. After re-
moval of duplicates, 108 articles were screened, 53 records were
found to be clearly irrelevant. The remaining 55 studies were re-
trieved in full-text or were conference abstracts, protocols or clini-
cal study results. The reports that did not appear tomeet our inclu-
sion criteria were excluded (nine reports). Five trials met our inclu-
sion criteria, and one study was a duplicate (Fauser 2010). We also
found two ongoing trials and one conference abstract with pre-
liminary results (Siristatidis 2011), for details see Characteristics
of ongoing studies.
We found on clinicaltrials.gov the protocols of the four included
studies and six protocols of follow up studies of the original in-
cluded studies. Clinical study reports of all protocols were found
on clinicalstudyresults.org.We included four trials and the data of
four conference abstracts, six protocols and six reports of clinical
study results in our meta-analyses. Overall, we included four trials.
Included studies
Study design and setting
Four randomised controlled trials were included in the review. All
were multi-center trials, conducted in Europe (Austria, Belgium,
Czech Republic, Denmark, Finland, France, Norway, Poland,
Spain, Sweden, The Netherlands, UK), North America (Canada,
USA) and Asia (Korea, Taiwan). We included two four-arm trials
(Devroey 2004; Koper 2008) and two two-arm trials (ENGAGE
2009; ENSURE2010). As there were studies with four arms, three
dosage arms and one control group, it was necessary to divide the
control group by three. If the study did not report live births per
dosage subgroup it was necessary to divide the intervention group
by three.Where this number was even, then we made an arbitrary
decision to increase or reduce the number of cases by one in one
of the three groups.
Participants
A total of 2335 women participated in the included studies, 1348
women in the intervention groups and 987 women in the control
groups. The age of the included participants ranged from 18 to
39 years, and the range of BMI was 17 to 32 kg/m2.
The inclusion criteria differed slightly between the studies in age,
BMI and weight. ENSURE 2010 included women with a body
weight ≤ 60 kg and BMI of 18 to 32 kg/m2, ENGAGE 2009
included women weighing > 60 kg and ≤ 90 kg with BMI 18 to
32 kg/m2. The two other studies included women weighing 50 to
90 kg (Devroey 2004; Koper 2008).
There were differences for the inclusion and exclusion criteria be-
tween the protocols and the published articles. Koper 2008 re-
ported an inclusion age range of 20 to 39 years in the article
while they stated 18 to 39 years in the protocol. Devroey 2004
reported none of the exclusion criteria as stated in the protocol.
All studies excluded poor responders, patients with a history of
OHSS or polycystic ovary syndrome (PCOS) (hyper-responders)
and women with explained subfertility.
A summary can be found in Table 1; for detail see table
Characteristics of included studies.
Interventions
All included studies compared long-acting FSH with daily FSH
and followedby aGnRHantagonist protocol. The studies varied in
initial dose of long-acting FSH administered: 454 women received
a low dose (60 to 120 µg) (Devroey 2004; ENSURE 2010; Koper
2008), 869 women received a medium dose (150 to 180 µg)
(Devroey 2004; ENGAGE 2009; Koper 2008) and 25 women
received a high dose (240 µg) (Devroey 2004). All studies used
rFSH for the control group: three studies used 150 IU rFSH (
Devroey 2004; ENSURE2010; Koper 2008) andENGAGE2009
used 200 IU rFSH. ENSURE 2010 and ENGAGE 2009 used a
bodyweight adjusted dose of long-acting and daily FSH.
GnRH antagonist was administered subcutaneously. Devroey
2004 started on the day the leading follicle reached 14 mm,
the three other studies (ENGAGE 2009; ENSURE 2010; Koper
2008) started on day 5. None of the studies used GnRH agonists.
The number of transferred embryos varied from one or two em-
bryos (ENGAGE 2009; ENSURE 2010) to three or fewer em-
bryos (Devroey 2004; Koper 2008), see Table 1.
Outcomes
Primary outcomes
Effectiveness
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Live birth rate was reported in four clinical trial reports with ad-
ditional data obtained by follow-up studies of the original trial.
Adverse
Ovarian hyperstimulation syndrome (OHSS) was reported in all
four included studies. We reported the total number of OHSS
cases, including mild, moderate and severe cases.
Secondary outcomes
Effectiveness
Clinical pregnancy rate was reported in three studies (ENGAGE
2009; ENSURE 2010; Koper 2008). These three studies reported
both the number of clinical pregnancies (defined as presence of
gestational sac confirmed by ultrasound) and the number of vital
pregnancies (defined as gestational sac and heartbeat confirmed
by ultrasound). We decided to report the vital pregnancy rate
per women randomised. Ongoing pregnancy rate was reported
by all four studies. If results after both fresh and frozen embryo
transfer were reported, wemade the decision to report the ongoing
pregnancy rate after fresh embryo transfer.
Adverse
Multiple pregnancy rate was reported in all four studies. Devroey
2004 reported three sets of twins in the intervention groups; we
assumed that one twin pregnancy occurred in each intervention
group. Miscarriage rate was reported in two studies (ENGAGE
2009; ENSURE 2010). Three studies reported ectopic preg-
nancy rate as an adverse event (Devroey 2004; ENGAGE 2009;
ENSURE 2010). We had insufficient data to report any other ad-
verse events.
Process
None of the included studies reported patient satisfaction with the
treatment.
Excluded studies
Eleven studies were excluded from the review. Two studies (Boost-
anfar 2011; Fauser 2010)were duplicates of ENGAGE 2009.Nine
studies did not meet our inclusion criteria, three studies were re-
views (Croxtall 2011; Ledger 2009; Seyhan 2011), five studies
(De Lartigue 2011; Fatemi 2010; Loutradis 2010; Norman 2011;
Prados 2011) were not randomised controlled trials (RCTs) and
one study (Balen 2004) was excluded because the women did not
undergo IVF or ICSI after the stimulation.
See table of Characteristics of excluded studies for details.
Risk of bias in included studies
The risk of bias was assessed for each included trial in the ’Risk of
bias’ table, see Characteristics of included studies. We summarised
our findings in the ’Risk of bias’ summary (see Figure 6) and in
the ’Risk of bias’ graph (see Figure 7).
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Figure 6. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 7. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
We contacted the authors for supplementary information. All in-
cluded studies had the same contact author; we did not receive the
requested data.
Allocation
Random sequence generation
All four included studieswere randomised.We judged three studies
at low risk of selection bias as they used randomly permutated
blocks with an undisclosed fixed block size (ENGAGE 2009;
ENSURE2010; Koper 2008).We judged one study at unclear risk
of selection bias related to random sequence generation because
the authors did not report the method of randomisation used
(Devroey 2004).
Allocation concealment
The allocation was concealed by using central remote allocation
in three studies and we judged the method to be at low risk of bias
(ENGAGE 2009; ENSURE 2010; Koper 2008). One study did
not describe the method of allocation concealment and we judged
this to be unclear risk of bias (Devroey 2004).
Blinding
Blinding of participants and personnel
All four studies reported their method of blinding. Two stud-
ies were open-label trials (Devroey 2004; Koper 2008) and were
judged at high risk of bias. Two studies were double-blind and de-
scribed use of a double-dummy placebo and were thus we deemed
them to be at low risk of performance bias (ENGAGE 2009;
ENSURE 2010).
Blinding of outcome assessment
Two of the studies did not report the blinding of outcome assessors
and we judged them to be at unclear risk of bias (ENGAGE 2009;
ENSURE 2010). The other two studies were open-label trials and
for this reason we judged them to be at high risk of detection bias
(Devroey 2004; Koper 2008)
Incomplete outcome data
Two studies were found to be at high risk of attrition bias. Devroey
2004 did not report reasons for all withdrawals. They reported in
their protocol six participants treated with long-acting FSH dur-
ing this trial; these treated participants were not analysed in their
publication. We decided to analyse 105 participants (99 partici-
pants analysed in the published paper and six participants treated
as stated in the protocol) in our meta-analysis.
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We foundENGAGE2009 tobe at high risk of bias because the trial
had a high unexplained drop-out rate. Two studies were judged
to be at low risk of bias because they reported all numbers and
reasons for withdrawals (ENSURE 2010; Koper 2008). Across all
studies, a total of 12.7% of participants in the intervention groups
and 7.5% in the control groups withdrew during the treatment
before embryo transfer.
Selective reporting
Protocols were available for all included studies and all pre-speci-
fied outcomes were reported in either the published articles or un-
published data on clinical study reports (clinicalstudyresults.gov).
We judged all four studies to be at low risk of reporting bias.
Other potential sources of bias
We judged all studies to be at high risk of other bias because the
included studies were funded by Schering-Plough (NVOrganon).
ENGAGE 2009 also received fees and grants from: Ferring,
Bessins, Serono, Merck Serono, IBSA, Wyeth, Schering, Ardana,
Andromed, Pantrhei Bioscience and Preglem.
Effects of interventions
See: Summary of findings for themain comparison Long-acting
FSH (all doses) versus daily FSH for women undergoing assisted
reproduction
We did not conduct all the subgroup analyses as stated in our pro-
tocol. We had insufficient data to be able to conduct the analyses,
see Table 1.We compared long-acting FSH (all doses) versus daily
FSH with the following subgroups.
Dose of long-acting FSH:
1. low dose (60 to 120 µg);
2. medium dose (150 to 180 µg);
3. high dose (240 µg).
Primary outcomes
1.1 Live birth rate
All four trials reported the numbers of live births. There was no
evidence of effect comparing long-acting FSH versus daily FSH.
Moderate heterogeneity was detected but there was no indication
of substantial heterogeneity (Peto OR 0.92; 95% CI 0.76 to 1.10,
4 RCTs, 2335 women, I2 = 46%).
1.1.1 Low dose
There was evidence of a reduced live birth rate in women who
received lower doses (60 to 120 µg) of long-acting FSH compared
to daily FSH (Peto OR 0.60; 95% CI 0.40 to 0.91, 3 RCTs, 645
women, I2 = 0%).
1.1.2 Medium dose
There was no evidence of difference in effect; heterogeneity was
detected but there was no indication of substantial heterogeneity
(Peto OR 1.03; 95% CI 0.84 to 1.27, 3 RCTs, 1647 women, I2
= 17%).
1.1.3 High dose
No data were available to conduct high dose subgroup analysis.
See Figure 8 for details.
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Figure 8. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.1 Live birth
rate.
1.2 Ovarian hyperstimulation syndrome (OHSS)
The primary adverse effect was reported in all four trials. There was
no evidence of effect for this adverse outcome andno heterogeneity
detected. (Peto OR 1.12; 95% CI 0.79 to 1.60, 4 RCTs, 2335
women, I2 = 0%).
1.2.1 Low dose
There was no evidence of difference in effect (Peto OR 1.22; 95%
CI 0.55 to 2.72, 3 RCTs, 645 women, I2 = 0).
1.2.2 Medium dose
There was no evidence of difference in effect; heterogeneity was
detected but there was no indication of substantial heterogeneity
(Peto OR 1.08; 95% CI 0.72 to 1.61, 3 RCTs, 1657 women, I2
= 49%).
1.2.3 High dose
There was no evidence of difference in effect (Peto OR 3.91; 95%
CI 0.15 to 104.40, 1 RCT, 33 women).
See Figure 9 for details.
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Figure 9. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.2 Ovarian
hyperstimulation syndrome.
Secondary outcomes
1.3 Ongoing pregnancy rate
All four included studies reported ongoing pregnancy rate. There
was no evidence of effect; heterogeneity was detected but no in-
dication for substantial heterogeneity (OR 0.93; 95% CI 0.78 to
1.11, 4 RCTs, 2334 women, I2 = 29%).
1.4.1 Low dose
There was no evidence of difference in effect; heterogeneity was
detected but there was no indication of substantial heterogeneity
(Peto OR 0.71; 95% CI 0.47 to 1.06, 3 RCTs, 645 women, I2 =
26%).
1.4.2 Medium dose
There was no evidence of difference in effect and no heterogeneity
detected. (Peto OR 1.02; 95% CI 0.83 to 1.25, 3 RCTs, 1656
women, I2 = 0%).
1.4.3 High dose
There was no evidence of difference in effect (Peto OR 0.30; 95%
CI 0.06 to 1.67, 1 RCT, 33 women).
See Figure 10 for details.
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Figure 10. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.3 Ongoing
pregnancy rate.
1.4 Clinical pregnancy rate
Clinical pregnancy rate was reported in three trials (ENGAGE
2009; ENSURE 2010; Koper 2008). There was no evidence of
effect, heterogeneity was detected but no indication for substantial
heterogeneity (PetoOR 0.96; 95%CI 0.80 to 1.15, 3 RCTs, 2230
women, I2 = 21%).
1.3.1 Low dose
There was no evidence of difference in effect and no heterogeneity
detected. (Peto OR 0.71; 95% CI 0.47 to 1.06, 2 RCTs, 610
women, I2 = 0%).
1.3.2 Medium dose
There was no evidence of difference in effect and no heterogeneity
detected. (Peto OR 1.03; 95% CI 0.84 to 1.26, 2 RCTs, 1620
women, I2 = 0%).
1.3.3 High dose
No data were available to conduct high dose subgroup analysis.
See Figure 11 for details
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Figure 11. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.4 Clinical
pregnancy rate.
1.5 Multiple pregnancy rate
The adverse event multiple pregnancy rate was reported in all four
studies. There was no evidence of effect (Peto OR 1.24; 95% CI
0.92 to 1.68, 4 RCTs, 2335 women, I2 = 0%).
1.5.1 Low dose
There was no evidence of difference in effect. Moderate hetero-
geneity detected, but no indication for substantial heterogeneity
(Peto OR 1.05; 95% CI 0.51 to 2.17, 3 RCTs, 645 women, I2 =
34%).
1.5.2 Medium dose
There was no evidence of difference in effect and no heterogeneity
detected (Peto OR 1.28; 95% CI 0.92 to 1.79, 3 RCTs, 1657
women, I2 = 0%).
1.5.3 High dose
There was no evidence of difference in effect (Peto OR 3.74; 95%
CI 0.04 to 362.67, 1 RCT, 33 women).
See Figure 12 for details.
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Figure 12. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.5 Multiple
pregnancy rate.
1.6 Miscarriage rate
Two studies reported the adverse eventmiscarriage rate (ENGAGE
2009; ENSURE 2010). There was no evidence of effect (Peto OR
1.27; 95% CI 0.76 to 2.12, 2 RCTs, 1905 women, I2 = 0%).
1.6.1 Low dose
There was no evidence of difference in effect (Peto OR 1.19; 95%
CI 0.38 to 3.73, 1 RCT, 396 women).
1.6.2 Medium dose
There was no evidence of difference in effect (Peto OR 1.29; 95%
CI 0.72 to 2.28, 1 RCT, 1509 women).
1.6.3 High dose
Not data were available to conduct high dose subgroup analysis.
See Figure 13 for details.
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Figure 13. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.6
Miscarriage rate.
1.7 Ectopic pregnancy rate
Three studies reported the adverse event ectopic pregnancy rate
(Devroey 2004; ENGAGE 2009; ENSURE 2010). There was no
evidence of effect and no heterogeneity was detected (Peto OR
0.91; 95% CI 0.43 to 1.92, 3 RCTs, 2004 women, I2 = 0%).
1.7.1 Low dose
There was no evidence of effect difference and no heterogeneity
was detected (Peto OR 1.05; 95% CI 0.32 to 3.42, 2 RCTs, 429
women, I2 = 0%).
1.7.2 Medium dose
There was no evidence of difference in effect and no heterogeneity
was detected (Peto OR 0.83; 95% CI 0.32 to 2.17, 2 RCTs, 1542
women, I2 = 0%).
1.7.3 High dose
There were no events in both the intervention group and the
control group.
See Figure 14 for details.
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Figure 14. Forest plot of comparison: 1 Long-acting FSH (all doses) versus daily FSH, outcome: 1.7 Ectopic
pregnancy rate.
D I S C U S S I O N
Summary of main results
This review evaluated the effectiveness of long-acting FSH versus
daily FSH on pregnancy and safety outcomes in women under-
going IVF or ICSI treatment cycles. There was evidence of a re-
duced live birth rate in women who received lower doses (60 to
120 µg) of long-acting FSH compared to daily FSH but no evi-
dence of difference in effect on live birth rate in women receiving
a medium dose (150 to 180 µg). Only one small study used a
high dose (240 µg) of long-acting FSH and at present this is of no
clinical value. The meta-analyses of effectiveness for the outcomes
of clinical pregnancy and ongoing pregnancy did not show evi-
dence of a difference of effect between long-acting and daily FSH.
Similarly, there was no evidence of a difference in adverse events
for OHSS rate, multiple pregnancy rate, miscarriage rate and ec-
topic pregnancy rate between long-acting and daily FSH. We can
conclude that medium dose long-acting FSH is a safe treatment
option, with no difference in benefits or harm.
See Summary of findings for the main comparison for a complete
overview.
Overall completeness and applicability of
evidence
All randomised clinical trials comparing long-acting FSH with
daily FSH were included in this review. Our primary outcomes,
live birth rate and OHSS rate, were reported in all four trials.
Women at high risk of OHSS (hyper-responders) were excluded;
this provides an explanation for the poor effect of long-acting FSH
on the OHSS rate and the low number of OHSS cases in both
treatment groups. Also, poor responders were excluded in all trials.
For this reason, trials did not provide outcome data on the use of
long-acting FSH in poor responders.
All studies excluded women with explained subfertility. Therefore,
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our meta-analyses were based on women with unexplained subfer-
tility. Our outcomes do not apply to long-acting FSH in women
with explained subfertility.
Quality of the evidence
We included four studies with a total of 2335 participants in our
meta-analyses. The number of participants in each study varied
between 99 and 1509. Both two-arm (one intervention and one
control group) and four-arm (three intervention groups and one
control group) studies were included. All studies reported their
outcomes per woman. Only one study performed an intention-
to-treat analysis but we had sufficient data to perform intention-
to-treat analyses. We found differences between the inclusion and
exclusion criteria as stated in the protocol and those published in
the article, see Characteristics of included studies for details. These
differences were minor and did not tend to be relevant.
The included studies differ in the dose of long-acting FSH.
ENGAGE 2009 and ENSURE 2010 used a dose adjusted for par-
ticipant body weight. ENGAGE 2009 only included women with
a body weight above 60 kg and they used a medium dose of long-
acting FSH. ENSURE 2010 recruited women weighing less than
60 kg and used a low dose of long-acting FSH for these women.
Both Devroey 2004 and Koper 2008 also used a low dose but they
included women weighing 50 to 90 kg. This may influence the
overall effect in the low dose, long-acting FSH subgroup in favour
of long-acting FSH.
Only one trial (Devroey 2004) studied a high dose of long-act-
ing FSH and this treatment subgroup contained only 25 partic-
ipants. This information is insufficient to make accurate conclu-
sions about the treatment with high dose, long-acting FSH.
None of the studies reported patient satisfaction for long-acting
FSH versus daily FSH treatment so we are not able to determine
if long-acting FSH treatment is more patient friendly than daily
FSH.
All included trials were sponsored by the same pharmaceutical
company and have the same contact author, from the company.
This may have introduced a bias in favour of long-acting FSH
treatment.
Two studies (Devroey 2004; Koper 2008) did not blind the partic-
ipants, personnel and outcome assessment and this caused a high
risk of bias. Two studies (Devroey 2004; ENGAGE 2009) did not
report all the reasons for withdrawals and Devroey 2004 did not
report six treated participants in their published article, constitut-
ing a high risk of bias. We detected some moderate heterogene-
ity between the studies and subgroups. This can be explained by
differences between the inclusion and exclusion criteria for par-
ticipants, participant characteristics and the small differences be-
tween the treatment after the first seven days of COS. There was
no indication for substantial heterogeneity, therefore we did not
perform sensitivity analyses.
Potential biases in the review process
We stated in our protocol that we would perform different sub-
group analyses. Due to insufficient data, we performed only the
subgroup analysis for dose of long-acting FSH. We included a
small number of studies and for this reason we did not construct a
funnel plot. Therefore, we were not able to estimate the existence
of publication or other reporting biases.
The method we adopted to deal with data from four-arm studies
(discussed in detail in Included studies) may have introduced bias.
All data were extracted by two review authors (AWP and CF).
AWP compared the extracted data and discussed disagreements
and doubts with CF. AWP entered the data into RevMan and
wrote the review. These authors’ methods may have introduced
bias.
Agreements and disagreements with other
studies or reviews
Our results are in agreement with both previous reviews (Croxtall
2011; Seyhan 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The use of a medium dose of long-acting FSH is a safe treatment
option and equally effective compared to daily FSH.
Implications for research
All current trials excluded poor- and hyper-responders to ovar-
ian stimulation and women with explained subfertility. There-
fore, further research is needed to determine if long-acting FSH
can be used in all women with subfertility. There is one ongoing
trial about long-acting FSH in combination with a GnRH agonist
treatment. More research is needed to determine the pregnancy
and safety outcomes in this treatment combination. There are no
studies about patient satisfaction with the treatment and further
research should examine this to determine whether the new treat-
ment is more patient friendly than the daily injections regimen.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Devroey 2004
Methods Randomised controlled trial, open-label four-arm trial
Academic multi-center trial; Belgium and The Netherlands
Timing: July 2001 to October 2002 (15 months)
Ethical approval and informed consent obtained
Power calculation carried out (dose of FSH-CTP)
No intention-to-treat analysis performed
Participants Number of participants as stated in their protocol (unpublished data): 104 (6 subjects
treated during stage I part of this trial)
Number of participants as stated in published article: 99 (75 intervention, 24 control
treated during phase II part of the trial)
All treated subjects (104) during the trial (phase I and II) are analysed in the follow-up
study. We decided to analyse 105 subjects (99 subjects analysed in the published paper
and 6 subjects treated stated in the protocol)
Inclusion criteria as stated in the article
Women between 18 and 39 years of age and a regular menstrual cycle (24-35 d) and
normal body weight (BMI 18-29 kg/m2)
Inclusion criteria as stated in the protocol
Women of couples with an indication for COH before IVF or ICSI, between 18 and 39
years, regular menstrual cycle (24-35d), BMI 18-29 kg/m2, couples have availability of
ejaculatory sperm, willing and able to sign informed consent
Exclusion criteria as stated in the article
Not reported
Exclusion criteria as stated in the protocol
History of/or current endocrine abnormality such as PCOS, or polycystic ovaries ac-
cording to USS, (treated) hyper-prolactinemia or evidence of ovarian dysfunction, > 3
unsuccessful COH cycles for IVF since last established ongoing pregnancy, history of
non- or low ovarian response to FSH/hMG treatment, any clinically relevant hormone
value outside the reference range during the early follicular phase as measured by the
local laboratory (FSH, LH, E2, P, total T, TSH and prolactin), any clinically relevant
abnormal laboratory value, any ovarian and/or abdominal abnormality interfering with
ultrasound examination, contraindications for the use of gonadotropins, epilepsy, dia-
betes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease,
history of alcohol or drug abuse within 12 months prior to signing informed consent,
hypersensitivity to Orgalutran® or any of its compounds, administration of investiga-
tional drugs within threemonths prior to screening, use of hormonal preparations within
one month prior to the start of Org 36286 with the exception of thyroid medication
Mean age (years) and SD
intervention 120 µg: 30.4 ± 3.8
intervention 180 µg: 31.5 ± 3.8
intervention 240 µg: 33.4 ± 4.1
control: 32.1 ± 4.3
Mean weight (kg) and SD: not reported
Mean BMI (kg/m2) and SD
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Devroey 2004 (Continued)
intervention 120 µg: 23.2 ± 2.8
intervention 180 µg: 22.9 ± 3.5
intervention 240 µg: 22.6 ± 2.7
control: 23.4 ± 2.8
Mean duration of subfertility (years) and SD
intervention 120 µg: 4.2 ± 3.1
intervention 180 µg: 4.9 ± 3.6
intervention 240 µg: 5.6 ± 4.3
control: 4.6 ± 3.2
Withdrawals
Intervention
Total 16% of participants in intervention groups withdrawn before embryo transfer
120 µg: two subjects who received hCG did not continue with oocyte pick-up, because
absence of sperm and too few pre-ovulatory follicles
180 µg: one randomised subject dropped-out before the treatment started, no reason
reported. One subject did not received hCGbecause an excessive response. Before oocyte
pick-up one subject discontinued because too few preovulatory follicles
240 µg: two subjects did not received hCG because an excessive response or a too-low
response
Six subjects in the intervention groups who had oocyte retrieval did not proceed with
embryo transfer because of fertilisation failure or the recovery of too few or no embryos
Control
Total 4.2% of participants in control group withdrawn before embryo transfer
One subject in the control group did not received hCG because a too-low response
Interventions Intervention: 120 µg, 180 µg or 240 µg long-acting FSH
Control: 150 IU rFSH
GnRH antagonist was administered sc starting on the day the leading follicle reached
14 mm, until at least 3 follicles ≥ 17 mm
No more than 3 embryos were transferred
Outcomes Primary
Live birth rate
OHSS
Secondary
Ongoing pregnancy rate
Multiple pregnancy rate
Adverse events: ectopic pregnancy
Notes They report in their protocol six subjects treated with long-acting FSH during the phase
I stage of this trial. Two subjects are treated with 120 µg and four subjects are treated
with 180 µg of long-acting FSH. These six subjects are not reported in their published
article. We made the decision to analyse all participants of this trial instead of the 99 as
reported in their article
Risk of bias
Bias Authors’ judgement Support for judgement
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Devroey 2004 (Continued)
Random sequence generation (selection
bias)
Unclear risk ”Randomised”
Method of randomisation not reported
Allocation concealment (selection bias) Unclear risk ”Randomised”
No reference to allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label trial
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label trial
Incomplete outcome data (attrition bias)
All outcomes
High risk Reason for one withdrawal not reported,
other numbers and reasons reported, for
details see Characteristics of included
studies
Selective reporting (reporting bias) Low risk All planned protocol outcomes reported
Other bias High risk Funded by pharmaceutical
ENGAGE 2009
Methods Randomised controlled trial, double-blind two-arm trial
Multicenter trial; 14 centres in North America (USA, Canada), 20 centres in Europe
( Spain, UK, Belgium, Czech Republic, Finland, France, Norway, Sweden, Denmark,
The Netherlands)
Timing June 2006 to January 2008 (20 months)
Ethical approval and informed consent obtained
Power calculation carried out (total no. of participants)
No intention-to-treat analysis performed
Participants Number of participants: 1509 (757 intervention, 752 control)
Inclusion criteria as stated in the article
Women aged 18-36 years with a body weight > 60kg and ≤ 90 kg, a BMI 18-32 kg/
m2, a menstrual cycle 24-35 d, access to ejaculatory sperm and an indication for COS
before IVF or ICSI
Inclusion criteria as stated in the protocol
Women of a couple with an indication for COS before IVF or ICSI, between 18 and 36
years with a regular menstrual cycle (24-35d), body weight > 60 kg an≤ 90 kg, BMI 18-
32 kg/m2 , couples have availability of ejaculatory sperm (donated and/or cryopreserved
sperm is allowed), willing and able to sign informed consent
Exclusion criteria as stated in the article
Patients who had a (history of ) an endocrine abnormality, an abnormal outcome of blood
biochemistry or hematology, an abnormal cervical smear, a chronic disease, relevant
ovarian, tubal or uterine pathology that could interfere with the COS treatment (e.g.
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endometrioma >0 mm or fibroids≥ 5 cm), embryo implantation or pregnancy were not
to be included in the trial. Patients who had a history of ovarian hyperresponse (more
than 30 follicles≥ 11 mm) or OHSS, PCOS or a basal antral follicle count of more than
20 on ultrasound (<11 mm, both ovaries combined). Other exclusion criteria included
a previously low ovarian response to FSH or hMG treatment (i.e. cycle cancelled due to
insufficient ovarian response or less than four oocytes obtained), an FSH or LH over 12
IU/L in the early follicular phase, more than three consecutive unsuccessful IVF cycles
since the last ongoing pregnancy, a history of recurrent miscarriage (three or more), or
currently smoking more than five cigarettes per day
Exclusion criteria as stated in the protocol
History of/or any current (treated) endocrine abnormality, history of ovarian hyper-
response or ovarian hyperstimulation syndrome (OHSS), history of/or current polycys-
tic ovary syndrome (PCOS), more than 20 basal antral follicles <11 mm (both ovaries
combined) as measured on USS in the early follicular phase (menstrual cycle day 2-5)
, less than 2 ovaries or any other ovarian abnormality (including endometrioma > 10
mm; visible on USS), presence of unilateral or bilateral hydrosalphinx (visible on USS)
, presence of any clinically relevant pathology affecting the uterine cavity or fibroids ≥
5 cm, more than three unsuccessful IVF cycles since the last established ongoing preg-
nancy (if applicable), history of non- or low ovarian response to FSH/hMG treatment,
history of recurrent miscarriage (3 or more, even when unexplained), FSH > 12 IU/L
or LH > 12 IU/L as measured by the local laboratory (sample taken during the early
follicular phase: menstrual cycle day 2-5), any clinically relevant abnormal laboratory
value based on a sample taken during the screening phase, contraindications for the
use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding,
hypersensitivity, ovarian cysts), recent history of/or current epilepsy, HIV infection, di-
abetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease, abnormal
karyotyping of the patient or her partner (if karyotyping is performed), smoking more
than 5 cigarettes per day, history or presence of alcohol or drug abuse within 12 months
prior to signing informed consent, previous use of Org 36286, use of hormonal prepara-
tions within 1 month prior to randomisation, hypersensitivity to any of the concomitant
medication prescribed as part of the treatment regimen in this protocol, administration
of investigational drugs within three months prior to signing informed consent
Mean age (years) and SD
intervention: 31.5 ± 3.3
control: 31.5 ± 3.2
Mean weight (kg) and SD
intervention: 68.8 ± 7.6
control: 68.4 ± 7.3
Mean BMI (kg/m2) and SD
intervention: 24.8 ± 2.8
control: 24.8 ± 2.7
Mean duration of subfertility (years) and SD
intervention: 3.3 ± 2.4
control: 3.2 ± 2.2
Withdrawals
Total intervention group: 11.2% withdrew before embryo transfer
Total control group: 6.4% withdrew before embryo transfer
A total of 187 patients failed screening or dropped out due to personal reasons prior to
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treatment allocation. Three patients (one in the intervention and two in the comparison
group) were discontinued prior to the start of treatment (one for personal reasons and
two were found to violate entry criteria after randomisation but before commencing
treatment). During the treatment, but before the embryo transfer, a total of 130 patients
(84 interventional, 46 control) discontinued the treatment, no reason reported
Interventions Intervention: 150 µg FSH-CTP
Control: 200 IU rFSH
GnRH antagonist was administered sc starting on day 5 up to and including the day of
hCG (at least 3 follicles ≥ 17 mm)
One ore two embryos were transferred
Drugs provided by patient itself, partner or medical staff
Outcomes Primary
Live birth rate
OHSS
Secondary
Clinical (vital) pregnancy rate
Ongoing pregnancy rate
Multiple pregnancy rate
Miscarriage rate
Adverse event: ectopic pregnancy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomisation to one of the two
arms (1:1 ratio) was done per centre and
stratified by age (<32 or ≥ 32 years) by
using randomly permutated blocks with a
’undisclosed’ fixed block size of four.”
Allocation concealment (selection bias) Low risk Quote: ”central remote allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (subject, investigator)
Quote: ”The double-dummy approach
guaranteed the blinding ofmedication dur-
ing the trial and prevented any bias in terms
of treatment decisions”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk High unexplained drop out rate, for details
see Characteristics of included studies
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Selective reporting (reporting bias) Low risk All planned protocol outcomes reported
Other bias High risk Funded by pharmaceuticals
ENSURE 2010
Methods Randomised controlled trial, double-blind two-arm trial
Multicentre trial; 14 centres in Europe (Austria, Czech republic, France, Spain, Poland,
Sweden, Denmark) and 5 centres in Asia (Korea, Taiwan)
Timing: January 2007 to December 2007 (12 months)
Ethical approval and informed consent obtained
Power calculation carried out (total no. participants)
Intention-to-treat analysis performed
Participants Number of participants: 396 (268 intervention, 128 control)
Inclusion criteria as stated in the article
Women aged 18-36 years, weighing ≤ 60 kg and BMI 18-32 kg/m2, normal menstrual
cycle (25-34d), have an indication for ovarian stimulation before IVF or ICSI, access to
ejaculatory spermatozoa
Inclusion criteria as stated in the protocol
Women aged 18-36 years, weighing ≤ 60 kg and BMI 18-32 kg/m2, normal menstrual
cycle (25-34d) and have an indication for IVF or ICSI, couples have availability of
ejaculatory sperm (donated and/or cryopreserved sperm allowed), willing and able to
sign informed consent
Exlusion criteria as stated in the article
Same as those reported in Devroey 2009; History of ovarian hyperresponse to ovarian
stimulation (more than 30 follicles >11 mm) or OHSS, PCOS or more than 20 basal
antral follicles on ultrasound (<11 mm, both ovaries combined), history of no or low
ovarian response (i.e. cycle cancelled due to insufficient response of less than four oocytes
obtained) or more than three unsuccessful ovarian stimulation cycles since the last es-
tablished ongoing pregnancy
Exclusion criteria as stated in the protocol
History of/or any current (treated) endocrine abnormality, history of ovarian hyper-re-
sponse or OHSS, history of/or current PCOS, more than 20 basal antral follicles <11
mm (both ovaries combined) as measured on USS in the early follicular phase (men-
strual cycle day 2-5), less than 2 ovaries or any other ovarian abnormality (including en-
dometrioma > 10 mm; visible on USS), presence of unilateral or bilateral hydrosalphinx
(visible on USS), presence of any clinically relevant pathology affecting the uterine cavity
or fibroids >= 5 cm, more than three unsuccessful IVF cycles since the last established
ongoing pregnancy (if applicable), history of non- or low ovarian response to FSH/hMG
treatment, history of recurrent miscarriage (3 or more, even when unexplained), FSH >
12 IU/L or LH > 12 IU/L as measured by the local laboratory (sample taken during the
early follicular phase: menstrual cycle day 2-5), any clinically relevant abnormal labora-
tory value based on a sample taken during the screening phase, contraindications for the
use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding,
hypersensitivity, ovarian cysts), recent history of/or current epilepsy, HIV infection, di-
abetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary disease, abnormal
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ENSURE 2010 (Continued)
karyotyping of the patient or her partner (if karyotyping is performed), smoking more
than 5 cigarettes per day, history or presence of alcohol or drug abuse within 12 months
prior to signing informed consent, previous use of Org 36286, use of hormonal prepara-
tions within 1 month prior to randomisation, hypersensitivity to any of the concomitant
medication prescribed as part of the treatment regimen in this protocol, administration
of investigational drugs within three months prior to signing informed consent
Mean age (years) and SD
intervention: 30.9 ± 3.2
control: 31.1 ± 3.0
Mean weight (kg) and SD
intervention: 54.1 ± 4.2
control: 54.4 ± 4.2
Mean BMI (kg/m2) and SD
intervention: 20.5 ± 1.5
control: 20.6 ± 1.6
Mean duration of subfertility (years) and SD
intervention: 3.2 ± 2.2
control: 3.3 ± 2.1
Withdrawals
Intervention
Total 8.2% of participants in intervention group
All the randomised patients started stimulation, two subjects cancelled the treatment
before hCG because of insufficient ovarian response and a patients decision. All hCG
treated patients underwent oocyte retrieval, twenty subjects cancelled before embryo
transfer, one because the risk of OHSS, one suspicious for tuberculosis, too high ovarian
response (5 subjects), no/too few/bad quality oocytes retrieved (2 subjects), no or abnor-
mal fertilisation (4 subjects), no/too few/bad quality embryos for transfer (7 subjects)
Control
Total 6.3% of participants in control group
All the randomised subjects started stimulation, one cancelled before the hCG treatment
because too high ovarian response. All hCG treated patients underwent oocyte retrieval,
a total of seven subjects discontinued before embryo transfer. The reasons are: no/too
few/bad oocytes retrieved (2 subjects), one subject because of too high ovarian response,
in one subject no fertilisation was possible, one had no/too few/bad quality embryos, no
or abnormal fertilisation (2 subjects)
Interventions Intervention: 100 µg long-acting FSH
Control: 150 IU rFSH
GnRH antagonist was administered sc starting on day 5 up to and including the day of
hCG (at least 3 follicles ≥ 17 mm)
One ore two embryos were transferred
Outcomes Primary
Live birth rate
Cumulative live birth rate
OHSS
Secondary
Clinical pregnancy rate
Ongoing pregnancy rate
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Multiple pregnancy rate
Miscarriage rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomisation to one of the two
treatment groups in a 2:1 ratio (investiga-
tional:reference group) was performed at
each centre and stratified by age (<32 or ≥
32 years) and planned fertilisation proce-
dure (IVF or ICSI) by central remote allo-
cation using randomly permutated blocks
with an ’undisclosed’ fixed block size of
three.”
Allocation concealment (selection bias) Low risk Quote: ”Randomisation by central remote
allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
”To conceal the allocation all patients also
started daily sc injectionof rFSHor placebo
on the same day, daily active or placebo
rFSH injections were continued through
the first seven days of stimulation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers and reasons for withdrawal re-
ported, for details see Characteristics of
included studies
Selective reporting (reporting bias) Low risk All planned protocol outcomes reported
Other bias High risk Funded by pharmaceutical
37Long-acting FSH versus daily FSH for women undergoing assisted reproduction (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Koper 2008
Methods Randomised controlled trial, open-label four-arm trial
Multicentre trial; 14 centres in Europe
Timing: May 2003 to May 2004 (12 months)
Ethical approval and informed consent obtained
Power calculation carried out (no. participants per group)
No intention-to-treat analyses performed
Participants Number of participants: 325 (242 intervention, 83 control)
Inclusion criteria as stated in the article
Women aged 20-39 years with a normal menstrual cycle (24-35d) and a BMI 17-31 kg/
m2 with an indication for COS before IVFor ICSI
Inclusion criteria as stated in the protocol
Women of couples with an indication for COH and IVF or ICSI, aged 18-39 years,
normal menstrual cycle (24-35d), BMI 17-31 kg/m2, with an indication for IVF or
ICSI, couples have availability of ejaculatory sperm (donated or frozen sperm is allowed)
, able and willing to sign informed consent
Exclusion criteria as stated in the article
Women with a history of OHSS, PCOS, any endocrine abnormality, previous poor
response to FSH or hCG, more than three unsuccessful COS cycles since last ongoing
pregnancy, fewer than two ovaries, abnormal hormone levels during days 2-7 of the
menstrual cycle, use of hormonal preparations within 1 month before treatment or
previous use of Corifollitropin alfa, were excluded
Exclusion criteria as stated in the protocol
History of/or any current (treated) endocrine abnormality, history of ovarian hyperstim-
ulation syndrome (OHSS), history of/or current polycystic ovary syndrome (PCOS) or
current polycystic ovaries according to USS (at least 10 follicles of 2-8 mm in each ovary)
, more than three unsuccessful COH cycles since the last established ongoing pregnancy
(if applicable), history of non- or low ovarian response to FSH/hMG treatment, any
clinically relevant hormone value outside the reference range during the early follicular
phase (menstrual cycle day 2-7) as measured by the local laboratory (FSH, LH, E2,
P, total T, TSH and prolactin), any clinically relevant abnormal laboratory value, less
than 2 ovaries, any ovarian and/or abdominal abnormality interfering with ultrasound
examination, contraindications for the use of gonadotropins (e.g. tumors, pregnancy/
lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts), epilepsy, dia-
betes, cardiovascular, gastro-intestinal, hepatic, renal, pulmonary, or abdominal disease,
history of presence of alcohol or drug abuse within 12 months prior to signing informed
consent, previous use of Org 36286, use of hormonal preparations within 1 month prior
to randomisation, hypersensitivity to Org 32489 (Puregon®) and/or Org 37462 (Orga-
lutran®) and/or Pregnyl® or any of their components, administration of investigational
drugs within three months prior to signing informed consent
Mean age (years) and SD
intervention 60 µg: 32.0 ± 3.5
intervention 120 µg: 32.0 ± 4.1
intervention 180 µg: 32.4 ± 3.5
control rFSH: 32.1 ± 3.8
Mean weight (kg) and SD
intervention 60 µg: 63.8 ± 9.0
intervention 120 µg: 64.8 ± 8.8
intervention 180 µg: 64.0 ± 9.3
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control rFSH: 65.2 ± 9.3
Mean BMI (kg/m2) and SD
intervention 60 µg: 22.7 ± 3.2
intervention 120 µg: 23.5 ± 3.2
intervention 180 µg: 22.7 ± 2.6
control rFSH: 23.1 ± 3.0
Mean duration of subfertility (years) and SD
intervention 60 µg: 3.2 ± 1.8
intervention 120 µg: 3.3 ± 1.9
intervention 180 µg: 3.1 ± 2.5
control rFSH: 3.1 ± 2.2
Withdrawals
58 subject are excluded before randomisation, reasons not reported
Interventions
Total 21.1% of participants in intervention groups withdrew before embryo transfer
60 µg: One subject excluded before stimulation because PCOS. 23 Subjects did not re-
ceived hCG because insufficient ovarian response (22 subjects) and one (serious) adverse
event. Five subjects are excluded before oocyte retrieval, two because insufficient ovarian
response, and two inadequate oocytes retrieved (none, too few or poor quality). Before
embryo transfer six subjects withdrew because no fertilisation (2 subjects, inadequate
embryos (3 subjects) and one because ICSI not possible (dead sperm)
120 µg: Three subjects excluded before start stimulation because personal reasons, five
did not underwent hCG treatment because insufficient ovarian response (2 subjects),
risk of hyperstimulation (2 subjects) and one for personal reasons. After oocyte retrieval
two excluded before transfer because no fertilisation or inadequate embryos
180 µg: Before the start of treatment four subjects are excluded because spontaneous
pregnancy (2 subjects) and personal reasons (2 subjects). After oocyte retrieval 4 subjects
did not underwent embryo transfer because risk of hyperstimulation, no fertilisation and
inadequate embryos (2 subjects)
Control
Total of 20.5% in control group withdrawn before embryo transfer
Two Subjects did not started stimulation because a menstrual disorder and personal
reasons, six subjects discontinued before the hCG treatment because insufficient ovarian
response (5 subjects) and one because personal reasons. Two subjects are excluded before
oocyte retrieval because an insufficient ovarian response and inadequate oocytes retrieved.
After oocyte retrieval seven subjects dropped-out because inadequate oocytes retrieved
(5 subjects) and in two subjects no fertilisation take place
Interventions Intervention: 60 µg, 120 µg or 180 µg long-acting FSH
Control: 150 IU rFSH
GnRH antagonist was administered sc starting on day 5 up to and including the day of
hCG (at least 3 follicles ≥ 17 mm)
No more than 3 embryos were transferred
Outcomes Primary
Live birth rate
OHSS
Secondary
Clinical (vital) pregnancy rate
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Ongoing pregnancy rate
Multiple pregnancy rate
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ”Randomisation to one of the four
arms (1:1:1:1) was stratified by age (<32
or ≥ 32 years) and by centre using a fixed
block size of four and a minimization al-
gorithm combined with randomly permu-
tated blocks.”
Allocation concealment (selection bias) Low risk Quote: ”Randomisation by using a central
remote allocation procedure”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers andmost reasons for withdrawals
reported, for details see Characteristics of
included studies
Selective reporting (reporting bias) Low risk All planned protocol outcomes reported
Other bias High risk Funded by pharmaceutical
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Balen 2004 This trial is excluded because no IVF or ICSI performed after stimulation
Croxtall 2011 Not a RCT (review)
De Lartigue 2011 Not a RCT
Fatemi 2010 Not a RCT
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Ledger 2009 Not a RCT (review)
Loutradis 2010 Not a RCT
Norman 2011 Not a RCT
Prados 2011 Not a RCT
Seyhan 2011 Not a RCT (review)
Characteristics of ongoing studies [ordered by study ID]
Pursue 2010
Trial name or title Efficacy and safety of a single injection of SCH 900962 versus daily recFSH injections in women undergoing
controlled ovarian stimulation (Study P06029)
Methods Randomised controlled trial, double-blind (Subject, Caregiver, Investigator, Outcomes Assessor), double-
dummy, two-arm trial
Participants Estimated enrolment: 1400 participants
Inclusion criteria
Willing and able to provide written informed consent for trial P06029 as well as for the Frozen-Thawed
Embryo Transfer (FTET) follow-up trial P06031, and for the pharmacogenetic analysis (if applicable), female
and ≥35 to ≤42 years of age with indication for COS and IVF/ICSI, body weight ≥50.0 kg, BMI ≥18.0
to ≤32.0 kg/m2, regular spontaneous menstrual cycle with variation not outside the 24-35 days, ejaculatory
sperm must be available (donated and/or cryopreserved sperm is allowed), results of clinical laboratory tests,
cervical smear, physical examination within normal limits or clinically acceptable to the investigator, adhere
to trial schedule
Exclusion criteria
A recent history of/or any current endocrine abnormality, a history of ovarian hyper-response or ovarian
hyperstimulation syndrome, a history of/or current polycystic ovary syndrome, more than 20 basal antral
follicles <11 mm (both ovaries combined) in the early follicular phase, less than 2 ovaries or any other ovarian
abnormality, unilateral or bilateral hydrosalpinx, intrauterine fibroids≥5 cm or any clinically relevant pathol-
ogy, which could impair embryo implantation or pregnancy continuation, more than three unsuccessful COS
cycles for IVF/ICSI since the last established ongoing pregnancy (if applicable), a history of non- or low
ovarian response to FSH/hMG treatment, a history of recurrent miscarriage, FSH >15.0 IU/L or LH >12.
0 IU/L during the early follicular phase, positive for HIV or Hepatitis B, contraindications for the use of
gonadotropins or GnRH antagonists, a recent history of/or current epilepsy, thrombophilia, diabetes, cardio-
vascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease requiring regular treatment,
smoking or recently stopped smoking (ie, within the last 3 months prior to signing informed consent), a
recent history or presence of alcohol or drug abuse, the subject or the sperm donor has known gene defects,
genetic abnormalities, or abnormal karyotyping, relevant for the current indication or for the health of the
offspring, prior or concomitant medications disallowed by protocol
Interventions Intervention: corifollitropin alfa, 100 µg for women weighing≤60 kg, and 150 µg for women weighing >60
kg
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Control: recombinant FSH 150-300 IU daily until > 2 follicles are >18 mm
Outcomes Primary:
Vital pregnancy (assessed by ultrasound at least 35 days after embryo transfer
Secondary:
Number of oocytes retrieved
Live birth rate
Starting date June 2010
Contact information No contacts provided
Notes Estimated study completion date: September 2012
Siristatidis 2011
Trial name or title Corifollitropin alfa versus recombinant follicle stimulating hormone (FSH) in ovarian stimulation of women
undergoing in vitro fertilisation
Methods Randomised controlled trial
Single-blind (participant), two-arm trial
One-centre trial
Participants Estimated enrolment: 100
Includion criteria
Women aged 18-36 years old with a body weight of more than 60 kg up to 90 kg, BMI of 18-32 kg/m2,
menstrual cycle length of 23-35 days, an indication for controlled ovarian stimulation for IVF or ICSI
Exclusion Criteria
History of an endocrine abnormality, abnormal outcome of blood biochemistry or hematology, abnormal
cervical smear, chronic disease, uterine pathology that interfering with the COS treatment (e.g. fibroids ≥ 5
cm)
Interventions Intervention: corifollitropin alfa 150 µg
Control: recombinant FSH 300 IU
Both GnRH agonists (long) and antagonists protocols will be used. Final oocyte maturation will be induced by
the administration of hCG on the day that 2 follicles >18 mmwere recognized on the transvaginal ultrasound
scan
One or two embryos will be transferred
Outcomes Primary:
Ongoing pregnancy rate, defined as the presence of fetal heart at ultrasound after 12 gestational weeks
Secondary:
Clinical pregnancy rate, defined as the presence of fetal heart at transvaginal ultrasound at 6+2 gestational
weeks
Cancellation rate
Miscarriage rate
Ectopic pregnancy rate
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Starting date January 2011
Contact information Siristatidis CS, MD, PhD; harrysiri@yahoo.gr, 6932294994 ext 0030
Notes Estimated completion date: January 2013
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D A T A A N D A N A L Y S E S
Comparison 1. Long-acting FSH (all doses) versus daily FSH
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Live birth rate 4 2335 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.92 [0.76, 1.10]
1.1 Low dose (60-120 µg) 3 645 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.60 [0.40, 0.91]
1.2 Medium dose (150-180
µg)
3 1657 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.84, 1.27]
1.3 High dose (240 µg) 1 33 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.29 [0.04, 1.95]
2 Ovarian hyperstimulation
syndrome
4 2335 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.12 [0.79, 1.60]
2.1 Low dose (60-120 µg) 3 645 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.55, 2.72]
2.2 Medium dose (150-180
µg)
3 1657 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.08 [0.72, 1.61]
2.3 High dose (240 µg) 1 33 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.91 [0.15, 104.40]
3 Ongoing pregnancy rate 4 2335 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.93 [0.78, 1.12]
3.1 Low dose (60-120 µg) 3 645 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.47, 1.06]
3.2 Medium dose (150-180
µg)
3 1657 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.02 [0.83, 1.25]
3.3 High dose (240 µg) 1 33 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.30 [0.06, 1.67]
4 Clinical pregnancy rate 3 2230 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.96 [0.80, 1.15]
4.1 Low dose (60-120 µg) 2 610 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.71 [0.47, 1.06]
4.2 Medium dose (150-180
µg)
2 1620 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.03 [0.84, 1.26]
5 Multiple pregnancy rate 4 2335 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.24 [0.92, 1.68]
5.1 Low dose (60-120 µg) 3 645 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.51, 2.17]
5.2 Medium dose (150-180
µg)
3 1657 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.28 [0.92, 1.79]
5.3 High dose (240 µg) 1 33 Peto Odds Ratio (Peto, Fixed, 95% CI) 3.74 [0.04, 362.67]
6 Miscarriage rate 2 1905 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.27 [0.76, 2.12]
6.1 Low dose (60-120 µg) 1 396 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.19 [0.38, 3.73]
6.2 Medium dose (150-180
µg)
1 1509 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.29 [0.72, 2.28]
7 Ectopic pregnancy rate 3 2004 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.91 [0.43, 1.92]
7.1 Low dose (60-120 µg) 2 429 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.05 [0.32, 3.42]
7.2 Medium dose (150-180
µg)
2 1542 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.83 [0.32, 2.17]
7.3 High dose (240 µg) 1 33 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 1 Live birth rate.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 1 Live birth rate
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
Devroey 2004 4/27 3/8 0.9 % 0.25 [ 0.04, 1.76 ]
ENSURE 2010 (1) 63/268 45/128 15.2 % 0.56 [ 0.35, 0.89 ]
Koper 2008 20/159 7/55 4.0 % 0.99 [ 0.39, 2.48 ]
Subtotal (95% CI) 454 191 20.1 % 0.60 [ 0.40, 0.91 ]
Total events: 87 (long-acting FSH), 55 (daily FSH)
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.015)
2 Medium dose (150-180 g)
Devroey 2004 4/29 3/8 0.9 % 0.22 [ 0.03, 1.60 ]
ENGAGE 2009 269/757 258/752 75.9 % 1.06 [ 0.85, 1.30 ]
Koper 2008 11/83 4/28 2.2 % 0.92 [ 0.26, 3.19 ]
Subtotal (95% CI) 869 788 78.9 % 1.03 [ 0.84, 1.27 ]
Total events: 284 (long-acting FSH), 265 (daily FSH)
Heterogeneity: Chi2 = 2.41, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.31 (P = 0.76)
3 High dose (240 g)
Devroey 2004 4/25 3/8 0.9 % 0.29 [ 0.04, 1.95 ]
Subtotal (95% CI) 25 8 0.9 % 0.29 [ 0.04, 1.95 ]
Total events: 4 (long-acting FSH), 3 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 1348 987 100.0 % 0.92 [ 0.76, 1.10 ]
Total events: 375 (long-acting FSH), 323 (daily FSH)
Heterogeneity: Chi2 = 11.10, df = 6 (P = 0.09); I2 =46%
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi2 = 6.71, df = 2 (P = 0.03), I2 =70%
0.05 0.2 1 5 20
Favours daily Favours long-acting
(1) This study only recruited women with a body weight of less than 60kg.
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Analysis 1.2. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 2 Ovarian
hyperstimulation syndrome.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 2 Ovarian hyperstimulation syndrome
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
Devroey 2004 2/27 1/8 1.6 % 0.53 [ 0.03, 8.55 ]
ENSURE 2010 (1) 18/268 6/128 16.2 % 1.43 [ 0.59, 3.44 ]
Koper 2008 2/159 1/55 1.9 % 0.67 [ 0.05, 9.01 ]
Subtotal (95% CI) 454 191 19.7 % 1.22 [ 0.55, 2.72 ]
Total events: 22 (long-acting FSH), 8 (daily FSH)
Heterogeneity: Chi2 = 0.67, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Medium dose (150-180 g)
Devroey 2004 0/29 1/8 0.6 % 0.01 [ 0.00, 1.15 ]
ENGAGE 2009 53/757 47/752 76.7 % 1.13 [ 0.75, 1.69 ]
Koper 2008 2/83 1/28 1.8 % 0.65 [ 0.05, 8.95 ]
Subtotal (95% CI) 869 788 79.1 % 1.08 [ 0.72, 1.61 ]
Total events: 55 (long-acting FSH), 49 (daily FSH)
Heterogeneity: Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 0.37 (P = 0.71)
3 High dose (240 g)
Devroey 2004 2/25 0/8 1.2 % 3.91 [ 0.15, 104.40 ]
Subtotal (95% CI) 25 8 1.2 % 3.91 [ 0.15, 104.40 ]
Total events: 2 (long-acting FSH), 0 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 1348 987 100.0 % 1.12 [ 0.79, 1.60 ]
Total events: 79 (long-acting FSH), 57 (daily FSH)
Heterogeneity: Chi2 = 5.25, df = 6 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.53)
Test for subgroup differences: Chi2 = 0.64, df = 2 (P = 0.73), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
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(1) This study only recruited women with a body weight of less than 60kg.
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Analysis 1.3. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 3 Ongoing pregnancy
rate.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 3 Ongoing pregnancy rate
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
Devroey 2004 4/27 3/8 0.9 % 0.25 [ 0.04, 1.76 ]
ENSURE 2010 (1) 68/268 44/128 14.9 % 0.64 [ 0.40, 1.02 ]
Koper 2008 24/159 7/55 4.3 % 1.21 [ 0.51, 2.88 ]
Subtotal (95% CI) 454 191 20.1 % 0.71 [ 0.47, 1.06 ]
Total events: 96 (long-acting FSH), 54 (daily FSH)
Heterogeneity: Chi2 = 2.71, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Medium dose (150-180 g)
Devroey 2004 5/29 3/8 0.9 % 0.31 [ 0.05, 2.04 ]
ENGAGE 2009 294/757 286/752 75.7 % 1.03 [ 0.84, 1.27 ]
Koper 2008 11/83 4/28 2.1 % 0.92 [ 0.26, 3.19 ]
Subtotal (95% CI) 869 788 78.8 % 1.02 [ 0.83, 1.25 ]
Total events: 310 (long-acting FSH), 293 (daily FSH)
Heterogeneity: Chi2 = 1.57, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
3 High dose (240 g)
Devroey 2004 6/25 4/8 1.1 % 0.30 [ 0.06, 1.67 ]
Subtotal (95% CI) 25 8 1.1 % 0.30 [ 0.06, 1.67 ]
Total events: 6 (long-acting FSH), 4 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 1348 987 100.0 % 0.93 [ 0.78, 1.12 ]
Total events: 412 (long-acting FSH), 351 (daily FSH)
Heterogeneity: Chi2 = 8.47, df = 6 (P = 0.21); I2 =29%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 4.19, df = 2 (P = 0.12), I2 =52%
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(1) This study only recruited women with a body weight of less than 60kg.
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Analysis 1.4. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 4 Clinical pregnancy
rate.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 4 Clinical pregnancy rate
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
ENSURE 2010 (1) 69/268 45/128 15.3 % 0.63 [ 0.40, 1.01 ]
Koper 2008 26/159 9/55 4.8 % 1.00 [ 0.44, 2.28 ]
Subtotal (95% CI) 427 183 20.1 % 0.71 [ 0.47, 1.06 ]
Total events: 95 (long-acting FSH), 54 (daily FSH)
Heterogeneity: Chi2 = 0.89, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
2 Medium dose (150-180 g)
ENGAGE 2009 302/757 293/752 77.5 % 1.04 [ 0.85, 1.28 ]
Koper 2008 12/83 5/28 2.4 % 0.77 [ 0.24, 2.52 ]
Subtotal (95% CI) 840 780 79.9 % 1.03 [ 0.84, 1.26 ]
Total events: 314 (long-acting FSH), 298 (daily FSH)
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Total (95% CI) 1267 963 100.0 % 0.96 [ 0.80, 1.15 ]
Total events: 409 (long-acting FSH), 352 (daily FSH)
Heterogeneity: Chi2 = 3.81, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Chi2 = 2.68, df = 1 (P = 0.10), I2 =63%
0.2 0.5 1 2 5
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(1) This study only recruited women with a body weight of less than 60kg.
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Analysis 1.5. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 5 Multiple pregnancy
rate.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 5 Multiple pregnancy rate
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
Devroey 2004 1/27 1/8 0.8 % 0.20 [ 0.01, 5.84 ]
ENSURE 2010 (1) 19/268 10/128 14.0 % 0.90 [ 0.40, 2.02 ]
Koper 2008 6/159 0/55 2.7 % 3.97 [ 0.62, 25.31 ]
Subtotal (95% CI) 454 191 17.5 % 1.05 [ 0.51, 2.17 ]
Total events: 26 (long-acting FSH), 11 (daily FSH)
Heterogeneity: Chi2 = 3.03, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Medium dose (150-180 g)
Devroey 2004 1/29 0/8 0.4 % 3.58 [ 0.03, 418.61 ]
ENGAGE 2009 83/757 66/752 79.9 % 1.28 [ 0.91, 1.79 ]
Koper 2008 3/83 1/28 1.7 % 1.01 [ 0.10, 9.98 ]
Subtotal (95% CI) 869 788 82.1 % 1.28 [ 0.92, 1.79 ]
Total events: 87 (long-acting FSH), 67 (daily FSH)
Heterogeneity: Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
3 High dose (240 g)
Devroey 2004 1/25 0/8 0.4 % 3.74 [ 0.04, 362.67 ]
Subtotal (95% CI) 25 8 0.4 % 3.74 [ 0.04, 362.67 ]
Total events: 1 (long-acting FSH), 0 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
Total (95% CI) 1348 987 100.0 % 1.24 [ 0.92, 1.68 ]
Total events: 114 (long-acting FSH), 78 (daily FSH)
Heterogeneity: Chi2 = 3.71, df = 6 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Chi2 = 0.46, df = 2 (P = 0.80), I2 =0.0%
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(1) This study only recruited women with a body weight of less than 60kg.
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Analysis 1.6. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 6 Miscarriage rate.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 6 Miscarriage rate
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
ENSURE 2010 (1) 10/268 4/128 20.3 % 1.19 [ 0.38, 3.73 ]
Subtotal (95% CI) 268 128 20.3 % 1.19 [ 0.38, 3.73 ]
Total events: 10 (long-acting FSH), 4 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 Medium dose (150-180 g)
ENGAGE 2009 27/757 21/752 79.7 % 1.29 [ 0.72, 2.28 ]
Subtotal (95% CI) 757 752 79.7 % 1.29 [ 0.72, 2.28 ]
Total events: 27 (long-acting FSH), 21 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 1025 880 100.0 % 1.27 [ 0.76, 2.12 ]
Total events: 37 (long-acting FSH), 25 (daily FSH)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
0.05 0.2 1 5 20
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(1) This study only recruited women with a body weight of less than 60kg.
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Analysis 1.7. Comparison 1 Long-acting FSH (all doses) versus daily FSH, Outcome 7 Ectopic pregnancy
rate.
Review: Long-acting FSH versus daily FSH for women undergoing assisted reproduction
Comparison: 1 Long-acting FSH (all doses) versus daily FSH
Outcome: 7 Ectopic pregnancy rate
Study or subgroup long-acting FSH daily FSH
Peto
Odds Ratio
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Low dose (60-120 g)
Devroey 2004 1/25 0/8 3.74 [ 0.04, 362.67 ]
ENSURE 2010 (1) 8/268 4/128 0.95 [ 0.28, 3.25 ]
Subtotal (95% CI) 293 136 1.05 [ 0.32, 3.42 ]
Total events: 9 (long-acting FSH), 4 (daily FSH)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Medium dose (150-180 g)
Devroey 2004 1/25 0/8 3.74 [ 0.04, 362.67 ]
ENGAGE 2009 7/757 9/752 0.77 [ 0.29, 2.07 ]
Subtotal (95% CI) 782 760 0.83 [ 0.32, 2.17 ]
Total events: 8 (long-acting FSH), 9 (daily FSH)
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
3 High dose (240 g)
Devroey 2004 0/25 0/8 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 25 8 0.0 [ 0.0, 0.0 ]
Total events: 0 (long-acting FSH), 0 (daily FSH)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 1100 904 0.91 [ 0.43, 1.92 ]
Total events: 17 (long-acting FSH), 13 (daily FSH)
Heterogeneity: Chi2 = 0.85, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
Favours daily Favours long-acting
(1) This study only recruited women with a body weight of less than 60kg.
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A D D I T I O N A L T A B L E S
Table 1. Summary of characteristics of included studies
Study ID Participant age
(years)
Participant
BMI (kg/m2)
Participant
weight (kg)
Start GnRH an-
tagonist
No. of embryos
transferred
Poor
responders
Devroey 2004 18-39 18-29 50-90 leading follicle >/
= 14mm
</=3 Excluded
ENGAGE 2009 18-36 18-32 >60 and </=90 Day 5 1 or 2 Excluded
ENSURE 2010 18-36 18-32 <60 Day 5 1 or 2 Excluded
Koper 2008 20-39
Protocol:18-39
17-31 50-90 Day 5 </=3 Excluded
A P P E N D I C E S
Appendix 1. Glossary
Assisted reproductive technology (ART)
All treatments or procedures that include the in vitro handling of human oocytes and sperm or embryos for the purpose of establishing
a pregnancy. This includes, but is not limited to, in vitro fertilization and transcervical embryo transfer, gamete intrafallopian transfer,
zygote intrafallopian transfer, tubal embryo transfer, gamete and embryo cryopreservation, oocyte and embryo donation, and gestational
surrogacy. ART does not include assisted insemination (artificial insemination) using sperm from either a woman’s partner or a sperm
donor.
Cancelled cycle
an ART cycle in which ovarian stimulation or monitoring has been carried out with the intent of undergoing ART but which did not
proceed to follicular aspiration or, in the case of a thawed embryo, to transfer.
Clinical pregnancy
Evidence of pregnancy by clinical or ultrasound parameters (ultrasound visualization of a gestational sac). It includes ectopic pregnancy.
Multiple gestational sacs in one patient are counted as one clinical pregnancy.
Controlled ovarian stimulation (COS)
Medical treatment to induce the development of multiple ovarian follicles to obtain multiple oocytes at follicular aspiration
Cryopreservation or cryostorage
Freezing and storage of gametes, zygotes, or embryos.
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Ectopic pregnancy
A pregnancy that occurs outside of the uterus.
Embryo
Product of conception from the time of fertilization to the end of the embryonic stage eight weeks after fertilization (the term pre-
embryo or dividing conceptus, has been replaced by embryo).
Embryo transfer (ET)
Procedure in which embryos are placed in the uterus or fallopian tube.
Fertilisation
The penetration of the ovum by the spermatozoon and fusion of genetic materials resulting in the development of a zygote.
Fetus
The product of conception starting from completion of embryonic development (at eight completed weeks after fertilisation) until
birth or abortion.
Follicle
The sac in which an egg develops in the ovary.
Follicle-stimulating hormone (FSH)
A hormone produced and released from the pituitary gland. In women it stimulates the production of oestrogen and follicles in the
ovary ready for ovulation. In men it stimulates the production of sperm.
Gestational age
Age of an embryo or foetus calculated by adding 14 days (2 weeks) to the number of completed weeks since fertilisation.
Gestational sac
A fluid-filled structure containing an embryo that develops early in pregnancy usually within the uterus.
Gonadotrophin releasing hormone (GnRH)
A substance produced by the hypothalamus (part of the brain) to enable the pituitary gland to secrete LH and FSH.
Gonadotropins
Pituitary hormones FSH and LH which stimulate the testes and ovaries.
Human chorionic gonadotrophin (hCG)
A hormone produced by placental tissue that can be measured in the blood and urine of pregnant women.
53Long-acting FSH versus daily FSH for women undergoing assisted reproduction (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hyper-responder
A women who produce a large number of oocytes (women with PCOS, see polycystic ovary syndrome, or a history of OHSS, see
ovarian hyperstimulation syndrome).
Implantation
The attachment and subsequent penetration by the zona-free blastocyst (usually in the endometrium) which starts five to seven days
following fertilization.
Intracytoplasmic sperm injection (ICSI)
When an egg is surgically removed from a woman and injected with a single spermatozoon is injected through the zona pellucida into
the oocyte . If fertilisation is successful the embryo is placed into the woman’s uterus. This technique is used when a male partner has
a low sperm count or other sperm related problem.
Intrauterine
Inside the uterus.
In vitro fertilization (IVF)
An ART procedure which involves extracorporeal fertilization.
Live birth
A birth in which a fetus is delivered with signs of life after complete expulsion or extraction from its mother, beyond 20 completed
weeks of gestational age. Live births are counted as birth events (e.g., a twin or triplet live birth is counted as one birth event).
Luteinising hormone (LH)
A hormone produced and released by the pituitary gland. In women it is responsible for ovulation and progesterone production. In
men it stimulates the production of testosterone and is involved with the production of sperm cells.
Miscarriage
Spontaneous end of a pregnancy at prior to 20 weeks of gestation.
Oocyte
The egg from a woman’s ovary.
Ova
A woman’s reproductive cell, also known as egg or oocyte.
Ovarian hyperstimulation syndrome (OHSS)
A condition that occurs from fertility drugs when a large number of follicles in the ovary are stimulated to develop and ovulate. This
stimulation causes an enlargement of the ovaries.
Ovulation
The release of an egg/ova from an ovarian follicle.
54Long-acting FSH versus daily FSH for women undergoing assisted reproduction (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ovulation Induction
Medical treatment to produce ovulation.
Ovulatory hCG (human chorionic gonadotrophin)
Hormone given to trigger ovulation in assisted reproduction.
Polycystic ovary syndrome (PCOS)
When a woman has enlarged ovaries with multiple cysts and the surface of the ovary is thickened. The woman may ovulate infrequently
or not at all.
Poor responder
A women who require large doses of medication to stimulate the ovary but produce less than an optimal number of oocytes.
Premature LH-surge
In a normal menstrual cycle an increase in LH-levels (LH-surge) is needed to start ovulation. In IVF/ICSI cycles it is important that
the ovulation does not start before the oocytes are mature enough to be retrieved. A LH-surge that occurs too early is called premature
and is an unwanted event in IVF/ICSI cycles.
Recombinant (as in recombinant FSH)
Is a naturally occurring hormone which has been made in the laboratory with the use of DNA technology. Recombinant technology
examines the DNA sequence of a hormone. The sequence is then placed inside certain bacteria (bacterial factories), which produce a
protein from the DNA sequence. This protein is then taken from the bacteria and packaged as a hormone.
Semen
A thick white fluid produced in the reproductive organs of men that usually contains the sperm cells produced in the testicles.
Spermatozoa/sperm
Male reproductive cells found in semen.
Subfertility
Failure to achieve pregnancy after at least one year of unprotected coitus.
Subcutaneous
Under the skin
Ultrasound
Radiology sounds waves of a high frequency used to examine the inside of the body. Ultrasound is also used to visualise the developing
foetus in the uterus to check size, growth and the presence of abnormalities.
Most of the definitions were achieved from the glossary of the MDSG module 2008.
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Appendix 2. CENTRAL search strategy
EBM Reviews - Cochrane Central Register of Controlled Trials (CENTRAL)
Date of search: 10-10-2011
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (1533)
2 embryo transfer$.tw. (853)
3 in vitro fertili?ation.tw. (1282)
4 ivf-et.tw. (244)
5 (ivf or et).tw. (5804)
6 icsi.tw. (626)
7 intracytoplasmic sperm injection$.tw. (389)
8 (blastocyst adj2 transfer$).tw. (63)
9 exp reproductive techniques, assisted/ or exp insemination, artificial/ or exp ovulation induction/ (2133)
10 assisted reproduct$.tw. (373)
11 artificial insemination.tw. (53)
12 iui.tw. (270)
13 intrauterine insemination$.tw. (373)
14 ovulation induc$.tw. (414)
15 ovarian hyperstimulation.tw. (524)
16 COH.tw. (117)
17 (ovari$ adj2 stimulat$).tw. (702)
18 superovulat$.tw. (127)
19 infertil$.tw. (1688)
20 subfertil$.tw. (127)
21 (ovari$ adj2 induction).tw. (25)
22 or/1-21 (8905)
23 corifollitropin alfa.tw. (12)
24 corifollitropin alpha.tw. (1)
25 org 36286.tw. (2)
26 org36286.tw. (0)
27 FSH carboxy terminal peptide.tw. (1)
28 FSH-CTP.tw. (5)
29 FSH CTP.tw. (5)
30 long acting follitropin.tw. (0)
31 Elonva$.tw. (0)
32 sustained follicle stimulat$.tw. (0)
33 long acting fsh.tw. (3)
34 long acting follicle stimulating hormone.tw. (0)
35 or/23-34 (14)
36 22 and 35 (7)
Appendix 3. MDSG search strategy
Date of search: 10-10-2011
Keywords CONTAINS “IVF”or“ICSI” or “subfertility” or “in vitro fertilisation” or “in vitro fertilization” or “intracytoplasmic sperm
injection” or “assisted conception” or “assisted reproduction” or “ART” or “infertility” or “IUI” or “Intrauterine Insemination” or “arti-
ficial insemination” or “ovarian hyperstimulation” or “ovarian stimulation” or “ovulation induction”or“COH” or “controlled ovarian ”
or “insemination” or “insemination-intrauterine” or Title CONTAINS “IVF”or“ICSI” or “subfertility” or “in vitro fertilisation” or “in
vitro fertilization” or “intracytoplasmic sperm injection” or “assisted conception” or “assisted reproduction” or “ART” or “infertility” or
“IUI” or “Intrauterine Insemination” or “artificial insemination” or “ovarian hyperstimulation” or “ovarian stimulation” or “ovulation
induction”or“COH” or “controlled ovarian ” or “insemination” or “insemination-intrauterine”
AND
Keywords CONTAINS “corifollitropin alfa” or Title CONTAINS “corifollitropin alfa”
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Appendix 4. MEDLINE search strategy
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE (1948 to
present)
Date of search: 10-10-2011
1 exp embryo transfer/ or exp fertilization in vitro/ or exp sperm injections, intracytoplasmic/ (29168)
2 embryo transfer$.tw. (7138)
3 in vitro fertili?ation.tw. (14924)
4 ivf-et.tw. (1669)
5 (ivf or et).tw. (154947)
6 icsi.tw. (4487)
7 intracytoplasmic sperm injection$.tw. (4173)
8 (blastocyst adj2 transfer$).tw. (424)
9 exp reproductive techniques, assisted/ or exp insemination, artificial/ or exp ovulation induction/ (47003)
10 assisted reproduct$.tw. (7212)
11 artificial insemination.tw. (4355)
12 iui.tw. (1012)
13 intrauterine insemination$.tw. (1571)
14 ovulation induc$.tw. (3109)
15 ovarian hyperstimulation.tw. (3292)
16 COH.tw. (894)
17 (ovari$ adj2 stimulat$).tw. (4178)
18 superovulat$.tw. (2718)
19 infertil$.tw. (36915)
20 subfertil$.tw. (2981)
21 (ovari$ adj2 induction).tw. (200)
22 or/1-21 (227905)
23 corifollitropin alfa.tw. (22)
24 corifollitropin alpha.tw. (1)
25 org 36286.tw. (4)
26 org36286.tw. (0)
27 FSH carboxy terminal peptide.tw. (2)
28 FSH-CTP.tw. (7)
29 FSH CTP.tw. (7)
30 long acting follitropin.tw. (1)
31 Elonva$.tw. (3)
32 sustained follicle stimulat$.tw. (5)
33 long acting fsh.tw. (13)
34 long acting follicle stimulating hormone.tw. (5)
35 or/23-34 (40)
36 22 and 35 (28)
37 randomized controlled trial.pt. (319965)
38 controlled clinical trial.pt. (83743)
39 randomized.ab. (234955)
40 placebo.tw. (137303)
41 clinical trials as topic.sh. (158838)
42 randomly.ab. (172143)
43 trial.ti. (100880)
44 (crossover or cross-over or cross over).tw. (52403)
45 or/37-44 (783234)
46 exp animals/ not humans.sh. (3701210)
47 45 not 46 (723312)
48 36 and 47 (11)
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Appendix 5. EMBASE search strategy
Embase.com (1980 to current)
Date of search: 10-10-2011
1 exp embryo transfer/ or exp fertilization in vitro/ or exp intracytoplasmic sperm injection/ (42896)
2 embryo$ transfer$.tw. (9711)
3 in vitro fertili?ation.tw. (17136)
4 ivf-et.tw. (2023)
5 icsi.tw. (6900)
6 intracytoplasmic sperm injection$.tw. (5013)
7 (blastocyst adj2 transfer$).tw. (667)
8 (ivf or et).tw. (299448)
9 exp infertility therapy/ or exp artificial insemination/ or exp intrauterine insemination/ or exp ovulation induction/ (63983)
10 artificial insemination.tw. (4135)
11 intrauterine insemination.tw. (1904)
12 assisted reproduct$.tw. (9674)
13 iui.tw. (1423)
14 ovulation induc$.tw. (3738)
15 (ovari$ adj2 stimulat$).tw. (5358)
16 ovarian hyperstimulation.tw. (4173)
17 COH.tw. (1095)
18 superovulat$.tw. (2637)
19 infertil$.tw. (43284)
20 subfertil$.tw. (3494)
21 (ovari$ adj2 induction).tw. (236)
22 or/1-21 (385118)
23 exp corifollitropin alfa/ (35)
24 corifollitropin alfa.tw. (46)
25 corifollitropin alpha.tw. (5)
26 FSH carboxy terminal peptide.tw. (1)
27 FSH-CTP.tw. (12)
28 FSH CTP.tw. (12)
29 long acting follitropin.tw. (1)
30 Elonva$.tw. (23)
31 sustained follicle stimulat$.tw. (9)
32 long acting fsh.tw. (16)
33 long acting follicle stimulating hormone.tw. (5)
34 org 36286.tw. (16)
35 org36286.tw. (0)
36 or/23-35 (82)
37 Clinical Trial/ (819367)
38 Randomized Controlled Trial/ (290224)
39 exp randomization/ (54690)
40 Single Blind Procedure/ (14260)
41 Double Blind Procedure/ (100996)
42 Crossover Procedure/ (30907)
43 Placebo/ (185441)
44 Randomi?ed controlled trial$.tw. (64940)
45 Rct.tw. (7766)
46 random allocation.tw. (1056)
47 randomly allocated.tw. (15613)
48 allocated randomly.tw. (1708)
49 (allocated adj2 random).tw. (688)
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50 Single blind$.tw. (11114)
51 Double blind$.tw. (118240)
52 ((treble or triple) adj blind$).tw. (247)
53 placebo$.tw. (159940)
54 prospective study/ (173744)
55 or/37-54 (1147610)
56 case study/ (13429)
57 case report.tw. (208273)
58 abstract report/ or letter/ (795123)
59 or/56-58 (1012785)
60 55 not 59 (1114252)
61 22 and 36 and 60 (35)
62 (2010$ or 2011$).em. (2228857)
63 61 and 62 (24)
Appendix 6. PsycINFO search strategy
PsycINFO (1980 to current)
Date of search: 10-10-2011
1 exp reproductive technology/ (1093)
2 in vitro fertili?ation.tw. (433)
3 ivf-et.tw. (16)
4 (ivf or et).tw. (78691)
5 icsi.tw. (37)
6 intracytoplasmic sperm injection$.tw. (30)
7 (blastocyst adj2 transfer$).tw. (2)
8 assisted reproduct$.tw. (379)
9 artificial insemination.tw. (202)
10 iui.tw. (17)
11 intrauterine insemination$.tw. (12)
12 ovulation induc$.tw. (13)
13 (ovari$ adj2 stimulat$).tw. (42)
14 superovulat$.tw. (5)
15 ovarian hyperstimulation.tw. (8)
16 COH.tw. (44)
17 infertil$.tw. (2154)
18 subfertil$.tw. (50)
19 (ovari$ adj2 induction).tw. (4)
20 or/1-19 (81563)
21 corifollitropin alfa.tw. (0)
22 corifollitropin alpha.tw. (0)
23 org 36286.tw. (0)
24 org36286.tw. (0)
25 FSH carboxy terminal peptide.tw. (0)
26 FSH-CTP.tw. (0)
27 FSH CTP.tw. (0)
28 long acting follitropin.tw. (0)
29 Elonva$.tw. (0)
30 sustained follicle stimulat$.tw. (0)
31 long acting fsh.tw. (0)
32 long acting follicle stimulating hormone.tw. (0)
33 exp Follicle Stimulating Hormone/ (71)
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34 Follicle Stimulating Hormone$.tw. (406)
35 FSH.tw. (329)
36 rFSH.tw. (0)
37 or/21-36 (520)
38 20 and 37 (27)
39 random.tw. (33464)
40 control.tw. (261118)
41 double-blind.tw. (15184)
42 clinical trials/ (5432)
43 placebo/ (2981)
44 exp Treatment/ (495944)
45 or/39-44 (748851)
46 38 and 45 (12)
Appendix 7. CINAHL search strategy
Date of search: 10-10-2011
# Results Query
S30 24 S17 and S29
S29 1036 S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28
S28 0 “ovarial hyperstimulation”
S27 216 “ovarian hyperstimulation”
S26 17 “controlled ovarian stimulation”
S25 103 “COS”
S24 31 “COH”
S23 298 “assisted reproduction”
S22 9 “assisted reproductive technique”
S21 157 “ICSI”
S20 8 “Intracytoplasmatic sperm injection”
S19 20 (MH “Fertilization in Vitro”)
S18 328 (MH “Embryo Transfer”)
S17 68 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or
S15 or S16
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(Continued)
S16 12 “recombinant FSH”
S15 7 “rFSH”
S14 53 (MH “Follicle-Stimulating Hormone”)
S13 0 “long-acting follicle stimulating hormone”
S12 0 “long acting follicle stimulating hormone”
S11 0 “FSH carboxy terminal peptide”
S10 0 “long acting FSH”
S9 0 “long-acting FSH”
S8 0 “FSH-CTP”
S7 0 “FSH CTP”
S6 0 “ORG36386”
S5 0 “ORG 36286”
S4 2 “Corifollitropin”
S3 0 “Elonva”
S2 0 “Corifollitropin alpha”
S1 2 “Corifollitropin alfa”
Appendix 8. ISI Web of Knowledge search strategy
Date of search: 10-10-2011
Set Results Search
#6 15 #4 AND #3
Refined by: Document Type=( MEETING )
Timespan=All Years
#5 96 #4 AND #3
Timespan=All Years
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(Continued)
#4 798 #2 AND #1
Timespan=All Years
#3 232,390 Topic=(embryo transfer) ORTopic=(in vitro fertilisation) ORTopic=(in vitro fertilization)
OR Topic=(ivf ) OR Topic=(icsi) OR Topic=(intracytoplasmatic sperm injections) OR
Topic=(artificial insemination) OR Topic=(intrauterine insemination) OR Topic=(ovula-
tion induction) OR Topic=(COS) OR Topic=(COH) OR Topic=(hyperstimulation) OR
Topic=(assisted reproduction) OR Topic=(assited reproduction technique)
Timespan=All Years
#2 60,600 Topic=(rFSH)ORTopic=(recombinant FSH)ORTopic=(recombinant follicle stimulating
hormone) OR Topic=(FSH)
Timespan=All Years
#1 674 Topic=(Corifollitropin) ORTopic=(Corifollitropin alfa) ORTopic=(Corifollitropin alpha)
OR Topic=(Elonva) OR Topic=(ORG36286) OR Topic=(ORG 36286) OR Topic=(FSH-
CTP) OR Topic=(FSH CTP) OR Topic=(long-acting FSH) OR Topic=(long acting FSH)
OR Topic=(FSH carboxy terminal peptide) OR Topic=(long acting follicle stimulating
hormone) OR Topic=(long-acting follicle stimulating hormone)
Timespan=All Years
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